| Year |
Citation |
Score |
| 2022 |
Hodis E, Triglia ET, Kwon JYH, Biancalani T, Zakka LR, Parkar S, Hütter JC, Buffoni L, Delorey TM, Phillips D, Dionne D, Nguyen LT, Schapiro D, Maliga Z, Jacobson CA, ... ... Garraway LA, et al. Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment. Science (New York, N.Y.). 376: eabi8175. PMID 35482859 DOI: 10.1126/science.abi8175 |
0.355 |
|
| 2022 |
Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mule JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, et al. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35190823 DOI: 10.1158/1078-0432.CCR-21-1060 |
0.49 |
|
| 2022 |
Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, ... ... Garraway LA, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate. PMID 35084050 DOI: 10.1002/pros.24305 |
0.621 |
|
| 2020 |
Zaidi SH, Harrison TA, Phipps AI, Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson P, Grasso CS, Giannakis M, Adams JB, Alwers E, Amitay EL, Barfield RT, Berndt SI, ... ... Garraway LA, et al. Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nature Communications. 11: 3644. PMID 32686686 DOI: 10.1038/S41467-020-17386-Z |
0.439 |
|
| 2020 |
Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P, Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, ... ... Garraway LA, et al. A single-cell landscape of high-grade serous ovarian cancer. Nature Medicine. PMID 32572264 DOI: 10.1038/S41591-020-0926-0 |
0.315 |
|
| 2020 |
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, ... ... Garraway L, et al. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine. PMID 32561875 DOI: 10.1038/S41591-020-0975-4 |
0.52 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, ... ... Garraway LA, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390 |
0.77 |
|
| 2020 |
Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER, Kalocsay M, Jané-Valbuena J, Gelfand E, Schweppe DK, Jedrychowski M, Golji J, Porter DA, Rejtar T, Wang YK, Kryukov GV, ... ... Garraway LA, et al. Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 180: 387-402.e16. PMID 31978347 DOI: 10.1016/J.Cell.2019.12.023 |
0.594 |
|
| 2020 |
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, ... ... Garraway LA, et al. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-09 |
0.662 |
|
| 2019 |
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, ... ... Garraway L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine. PMID 31792460 DOI: 10.1038/S41591-019-0654-5 |
0.596 |
|
| 2019 |
Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews. Drug Discovery. PMID 31712683 DOI: 10.1038/S41573-019-0046-Z |
0.346 |
|
| 2019 |
Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, ... ... Garraway LA, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10: 4346. PMID 31554815 DOI: 10.1038/S41467-019-12361-9 |
0.662 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Garraway LA, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243 |
0.384 |
|
| 2019 |
Amin-Mansour A, George S, Sioletic S, Carter SL, Rosenberg M, Taylor-Weiner A, Stewart C, Chevalier A, Seepo S, Tracy A, Getz G, Hornick JL, Nucci MR, Quade B, Demetri GD, ... ... Garraway LA, et al. Genomic evolutionary patterns of leiomyosarcoma and liposarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31164371 DOI: 10.1158/1078-0432.Ccr-19-0271 |
0.533 |
|
| 2019 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, ... ... Garraway LA, et al. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 31152158 DOI: 10.1038/S41588-019-0451-6 |
0.564 |
|
| 2019 |
Li H, Ning S, Ghandi M, Kryukov GV, Gopal S, Deik A, Souza A, Pierce K, Keskula P, Hernandez D, Ann J, Shkoza D, Apfel V, Zou Y, Vazquez F, ... ... Garraway LA, et al. The landscape of cancer cell line metabolism. Nature Medicine. 25: 850-860. PMID 31068703 DOI: 10.1038/S41591-019-0404-8 |
0.771 |
|
| 2019 |
Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Garraway LA, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3 |
0.783 |
|
| 2019 |
Hayes TK, Luo F, Cohen O, Goodale AB, Lee Y, Pantel S, Bagul M, Piccioni F, Root DE, Garraway LA, Meyerson M, Johannessen CM. A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma. Cancer Research. PMID 30819666 DOI: 10.1158/0008-5472.Can-18-2711 |
0.372 |
|
| 2019 |
Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas. Cancer Discovery. PMID 30709805 DOI: 10.1158/2159-8290.Cd-18-0879 |
0.377 |
|
| 2019 |
Jerby L, Shah P, Cuoco MS, Rodman C, Su M, Melms JM, Leeson R, Kanodia A, Mei S, Lin J, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Garraway LA, et al. Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A082 |
0.42 |
|
| 2019 |
Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... ... Garraway L, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14 |
0.409 |
|
| 2019 |
Izar B, Jerby-Arnon L, Tirosh I, Shah P, Cuoco MC, Rodman C, Su M, Melms JC, Leeson R, Kanodia A, Lin J, Boland GM, Zhang G, Hodi FS, Sorger PK, ... ... Garraway LA, et al. Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Sy45-04 |
0.32 |
|
| 2019 |
Cohen O, Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock D, Leshchiner I, Dellostritto L, Garrido-Castro A, ... ... Garraway L, et al. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-02 |
0.539 |
|
| 2019 |
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo M, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, ... ... Garraway LA, et al. Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Sy05-03 |
0.511 |
|
| 2019 |
Zaidi S, Phipps A, Harrison T, Grasso C, Steinfelder R, Trinh Q, Connolly C, Banbury B, Rafikova A, Hofer P, Brezina S, Giannakis M, Mu XJ, Quist M, Fuchs C, ... Garraway L, et al. Abstract 1224: Deep targeted tumor sequencing of colorectal cancer cases to study associations of molecular subtypes with clinical, genetic, and lifestyle risk factors Cancer Research. 78: 1224-1224. DOI: 10.1158/1538-7445.Am2018-1224 |
0.485 |
|
| 2018 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Garraway LA, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. PMID 30559381 DOI: 10.1038/S41586-018-0722-X |
0.745 |
|
| 2018 |
Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Garraway LA, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 175: 984-997.e24. PMID 30388455 DOI: 10.1016/J.Cell.2018.09.006 |
0.606 |
|
| 2018 |
Porter KM, Kauffman TL, Koenig BA, Lewis KL, Rehm HL, Richards CS, Strande NT, Tabor HK, Wolf SM, Yang Y, Amendola LM, Azzariti DR, Berg JS, Bergstrom K, Biesecker LG, ... ... Garraway LA, et al. Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. Molecular Genetics & Genomic Medicine. PMID 30133189 DOI: 10.1002/Mgg3.453 |
0.34 |
|
| 2018 |
Sandoval GJ, Pulice JL, Pakula H, Schenone M, Takeda DY, Pop M, Boulay G, Williamson KE, McBride MJ, Pan J, St Pierre R, Hartman E, Garraway LA, Carr SA, Rivera MN, et al. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Molecular Cell. PMID 30078722 DOI: 10.1016/J.Molcel.2018.06.040 |
0.336 |
|
| 2018 |
Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, ... ... Garraway LA, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discovery. PMID 29903880 DOI: 10.1158/2159-8290.Cd-18-0275 |
0.666 |
|
| 2018 |
Hamada T, Soong TR, Masugi Y, Kosumi K, Nowak JA, da Silva A, Mu XJ, Twombly TS, Koh H, Yang J, Song M, Liu L, Gu M, Shi Y, Nosho K, ... ... Garraway LA, et al. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 7: e1442999. PMID 29900052 DOI: 10.1080/2162402X.2018.1442999 |
0.435 |
|
| 2018 |
Konieczkowski DJ, Johannessen CM, Garraway LA. A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell. 33: 801-815. PMID 29763622 DOI: 10.1016/J.Ccell.2018.03.025 |
0.388 |
|
| 2018 |
Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, ... ... Garraway LA, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. PMID 29656892 DOI: 10.1016/J.Cell.2018.03.026 |
0.616 |
|
| 2018 |
Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, ... ... Garraway LA, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism. PMID 29628419 DOI: 10.1016/J.Cmet.2018.02.024 |
0.424 |
|
| 2018 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, ... ... Garraway LA, et al. The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 29610475 DOI: 10.1038/S41588-018-0078-Z |
0.655 |
|
| 2018 |
Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, ... ... Garraway LA, et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discovery. PMID 29510987 DOI: 10.1158/2159-8290.Cd-17-1327 |
0.449 |
|
| 2018 |
AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T, Mu XJ, Nishihara R, Qian Z, Liu L, Yurgelun MB, Syngal S, Garraway LA, Ogino S, Fuchs CS, et al. Inherited DNA-Repair Defects in Colorectal Cancer. American Journal of Human Genetics. PMID 29478780 DOI: 10.1016/J.Ajhg.2018.01.018 |
0.618 |
|
| 2018 |
Izar B, Jerby-Arnon L, Rotem A, Shah P, Liu D, Zhang G, Schilling B, Rozenblatt-Rosen O, Boland GM, Hodi FS, Flaherty K, Van Allen EM, Johnson BE, Schadendorf D, Yoon C, ... Garraway LA, et al. Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. Journal of Clinical Oncology. 36: 3074-3074. DOI: 10.1200/Jco.2018.36.15_Suppl.3074 |
0.316 |
|
| 2018 |
Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016. DOI: 10.1200/Jco.2018.36.15_Suppl.12016 |
0.742 |
|
| 2018 |
Giannakis M, Grasso C, Wells D, Hamada T, Mu XJ, Quist M, Nowak J, Nishihara R, Connolly CM, Shukla S, Grady WM, Wheeler D, Wu CJ, Zaretsky J, Garraway L, et al. Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Pr03 |
0.474 |
|
| 2018 |
Mo SS, Liu D, Gray SW, Joffe S, Wagle N, Garber J, Garraway LA, Sholl L, Janne PA, Allen EMV. Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer Cancer Research. 78: 3254-3254. DOI: 10.1158/1538-7445.Am2018-3254 |
0.694 |
|
| 2017 |
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, ... ... Garraway LA, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications. 8: 2193. PMID 29259186 DOI: 10.1038/S41467-017-02320-7 |
0.66 |
|
| 2017 |
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, ... ... Garraway L, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706. PMID 29208398 DOI: 10.1016/S1470-2045(17)30698-8 |
0.407 |
|
| 2017 |
Sanghvi RV, Buhay CJ, Powell BC, Tsai EA, Dorschner MO, Hong CS, Lebo MS, Sasson A, Hanna DS, McGee S, Bowling KM, Cooper GM, Gray DE, Lonigro RJ, Dunford A, ... ... Garraway L, et al. Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 29144510 DOI: 10.1038/Gim.2017.192 |
0.604 |
|
| 2017 |
Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, ... ... Garraway LA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications. 8: 1324. PMID 29109393 DOI: 10.1038/S41467-017-00965-Y |
0.745 |
|
| 2017 |
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, ... ... Garraway LA, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.Cd-17-0833 |
0.576 |
|
| 2017 |
Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, ... ... Garraway LA, et al. Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Systems. 5: 105-118.e9. PMID 28837809 DOI: 10.1016/J.Cels.2017.08.002 |
0.627 |
|
| 2017 |
Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, ... ... Garraway LA, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature Medicine. PMID 28805821 DOI: 10.1038/Nm.4372 |
0.492 |
|
| 2017 |
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, ... ... Garraway LA, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine. PMID 28805820 DOI: 10.1038/Nm.4378 |
0.464 |
|
| 2017 |
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, ... ... Garraway L, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993 |
0.74 |
|
| 2017 |
McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW. The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine. 14: 37-50. PMID 28757884 DOI: 10.2217/Pme-2016-0074 |
0.7 |
|
| 2017 |
Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM, Meyers RM, Ali L, Goodale A, Lee Y, Jiang G, ... ... Garraway LA, et al. Defining a Cancer Dependency Map. Cell. 170: 564-576.e16. PMID 28753430 DOI: 10.1016/J.Cell.2017.06.010 |
0.466 |
|
| 2017 |
Nirschl CJ, Suárez-Fariñas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, Liu Y, Zhu Q, Devi KSP, Carroll SL, Chau D, Rezaee M, Kim TG, Huang R, Fuentes-Duculan J, ... ... Garraway L, et al. IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell. 170: 127-141.e15. PMID 28666115 DOI: 10.1016/J.Cell.2017.06.016 |
0.318 |
|
| 2017 |
Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, ... ... Garraway LA, et al. Systematic genomic and translational efficiency studies of uveal melanoma. Plos One. 12: e0178189. PMID 28594900 DOI: 10.1371/Journal.Pone.0178189 |
0.721 |
|
| 2017 |
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, ... ... Garraway LA, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discovery. PMID 28515055 DOI: 10.1158/2159-8290.Cd-16-0960 |
0.64 |
|
| 2017 |
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology. 18: 80. PMID 28464947 DOI: 10.1186/S13059-017-1183-5 |
0.698 |
|
| 2017 |
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, ... ... Garraway L, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine. 9: 34. PMID 28420421 DOI: 10.1186/S13073-017-0424-2 |
0.375 |
|
| 2017 |
Garraway L. Remember why we work on cancer. Nature. 543: 613-615. PMID 28358103 DOI: 10.1038/543613A |
0.374 |
|
| 2017 |
Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, ... ... Garraway LA, et al. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 28125075 DOI: 10.1038/Gim.2016.191 |
0.732 |
|
| 2017 |
Sun Y, Alberta JA, Pilarz C, Calligaris D, Chadwick EJ, Ramkissoon SH, Ramkissoon LA, Garcia VM, Mazzola E, Goumnerova L, Kane M, Yao Z, Kieran MW, Ligon KL, Hahn WC, ... Garraway LA, et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro-Oncology. PMID 28082416 DOI: 10.1093/Neuonc/Now261 |
0.345 |
|
| 2017 |
Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, Shah P, Rotem A, Garraway LA, Sorger PK. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Molecular Systems Biology. 13: 905. PMID 28069687 DOI: 10.15252/Msb.20166796 |
0.375 |
|
| 2017 |
Huang FW, Rinne ML, Lundgren KT, Mullane SA, Moreno I, Reed S, Gydush G, Adalsteinsson V, Novak J, Hahn WC, Signoretti S, Choueiri TK, Garraway LA, Bellmunt J. Cell-free tumor DNA and TERT promoter mutations in bladder cancer. Journal of Clinical Oncology. 35: 353-353. DOI: 10.1200/Jco.2017.35.6_Suppl.353 |
0.45 |
|
| 2017 |
Armenia J, Mullane SA, Gao J, Chakravarty D, Kundra R, Huang FW, Han GC, Robinson D, Garraway LA, Nelson P, Rubin MA, Taplin M, Abida W, Sawyers CL, Chinnaiyan AM, et al. The long tail of significantly mutated genes in prostate cancer. Journal of Clinical Oncology. 35: 131-131. DOI: 10.1200/Jco.2017.35.6_Suppl.131 |
0.477 |
|
| 2017 |
Rohanizadegan M, Aldubayan SH, Giannakis M, Mu XJ, Nishihara R, Qian ZR, Nowak J, Cao Y, Liu L, Song M, Chan AT, Garraway LA, Ogino S, Fuchs CS, Van Allen EM. Clinical actionability of germline testing in patients with limited colorectal polyps. Journal of Clinical Oncology. 35: e13027-e13027. DOI: 10.1200/Jco.2017.35.15_Suppl.E13027 |
0.383 |
|
| 2017 |
Giannakis M, Li H, Jin C, Gopal S, Desai K, Horak C, Wind-Rotolo M, Van Allen EM, Clish C, Hodi FS, Garraway LA, Choueiri TK. Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients. Journal of Clinical Oncology. 35: 3036-3036. DOI: 10.1200/Jco.2017.35.15_Suppl.3036 |
0.311 |
|
| 2017 |
Aldubayan SH, Giannakis M, Moore N, Mu XJ, Han GC, Nishihara R, Qian ZR, Liu L, Ogino S, Garraway LA, Fuchs CS, Van Allen EM. Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer. Journal of Clinical Oncology. 35: 1500-1500. DOI: 10.1200/Jco.2017.35.15_Suppl.1500 |
0.416 |
|
| 2017 |
Tsherniak A, Vazquez F, Weir B, Montgomery P, Cowley G, Gill S, Kryukov G, Pantel S, Harrington W, Burger M, Meyers R, Ali L, Goodale A, Lee Y, Garraway L, et al. Abstract PR02: Towards a Cancer Dependency Map Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Pr02 |
0.495 |
|
| 2017 |
Meyers RM, Aguirre AJ, Weir BA, Vazquez F, Zhang C, Ben-David U, Cook A, Ha G, Harrington WF, Doshi M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, ... ... Garraway LA, et al. Abstract B39: Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B39 |
0.454 |
|
| 2017 |
Stover E, Howitt B, Garraway L, Matulonis U. Abstract MIP-075: SOMATIC MUTATIONS AND COPY-NUMBER VARIATIONS IN OVARIAN CANCERS VIA TARGETED SEQUENCING OF EXONS OF 300 CANCER-ASSOCIATED GENES, INCLUDING MULTIPLE DNA DAMAGE REPAIR GENES Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Mip-075 |
0.51 |
|
| 2017 |
Izar B, Stover E, Tirosh I, Rotem A, Shah P, Rodman C, Prakadan S, Wadsworth M, Su M, Leeson R, Palakurthi S, Liu J, Matulonis U, Shalek A, Rozenblatt-Rosen O, ... ... Garraway L, et al. Abstract AP19: SINGLE–CELL RNA–SEQUENCING OF PATIENT–DERIVED OVARIAN CANCER CELLS AND PATIENT–DERIVED XENOGRAFT MODELS Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap19 |
0.453 |
|
| 2017 |
Mouw K, Lazaro J, Damish A, Reznichenko E, Frazier Z, Liu D, Kim J, Polak P, Garraway L, Getz G, Rosenberg J, Allen EV, D'Andrea A. Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-Pr18 |
0.447 |
|
| 2017 |
Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin J, Boswell SA, Garraway LA, Sorger PK. Abstract PR17: Single-cell analysis reveals an adaptive, slowly-dividing, de-differentiated, drug-resistant cell state selectively inhibitable by drug combinations Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr17 |
0.359 |
|
| 2017 |
Hong AL, Tseng Y, Kynnap BD, Doshi MB, Sandoval G, Oh C, Sayeed A, Shubhroz G, Church AJ, Keskula P, Peng A, Clemons PA, Tsherniak A, Vazquez F, Rodriguez-Galindo C, ... ... Garraway LA, et al. Abstract B17: Identification of Druggable Targets through Functional Multi-Omics in Renal Medullary Carcinoma Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B17 |
0.412 |
|
| 2017 |
Wong T, Johannessen C, Fan J, Long H, Liu S, Garraway L. Abstract B15: Comprehensive cistromic characterization of SOX10, a lineage-specific genetic dependency in melanoma, via the integration of functional genomic approaches Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B15 |
0.488 |
|
| 2017 |
Tseng Y(, Hong A, Gill S, Keskula P, Raghavan S, Cheah J, Tsherniak A, Vazquez F, Alkhairy S, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, Garraway L, et al. Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A02 |
0.688 |
|
| 2017 |
Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, ... ... Garraway L, et al. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S1-01 |
0.639 |
|
| 2017 |
Nishihara R, Chan AT, Mu JX, Giannakis M, Mima K, Qian ZR, Bullman S, Kostic AD, Huttenhower C, Garrett W, Giovannucci EL, Meyerson M, Garraway LA, Fuchs CS, Ogino S. Abstract PR01:Fusobacterium nucleatumand mutational landscape of colorectal cancer in whole-exome sequencing analysis Cancer Research. 77. DOI: 10.1158/1538-7445.Crc16-Pr01 |
0.443 |
|
| 2017 |
Miao D, Liu D, Keliher D, Shukla S, Schilling B, Margolis C, Smart A, Garraway L, Hodi S, Schadendorf D, Allen EMV. Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma Cancer Research. 77: 571-571. DOI: 10.1158/1538-7445.Am2017-571 |
0.427 |
|
| 2017 |
Smart AC, Margolis C, Miao D, Liu D, Park J, He MX, Reardon B, Mullane S, Schilling B, Garraway LA, Schadendorf D, Allen EMV. Abstract 5647: Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy Cancer Research. 77: 5647-5647. DOI: 10.1158/1538-7445.Am2017-5647 |
0.436 |
|
| 2017 |
Armenia J, Mullane S, Gao J, Chakravarty D, Kundra R, Huang F, Han C, Robinson D, Garraway LA, Nelson P, Rubin M, Taplin M, Abida W, Sawyers CL, Chinnaiyan AM, et al. Abstract 3566: The long tail of significantly mutated genes in prostate cancer Cancer Research. 77: 3566-3566. DOI: 10.1158/1538-7445.Am2017-3566 |
0.405 |
|
| 2017 |
Izar B, Tirosh I, Stover E, Rotem A, Shah P, Cuoco M, Rodman C, Liu J, Matulonis U, Rozenblatt-Rosen O, Garraway L, Regev A. Abstract 3037: Dissecting treatment resistance in patients with ovarian cancer and PDX-models using single-cell RNA-sequencing Cancer Research. 77: 3037-3037. DOI: 10.1158/1538-7445.Am2017-3037 |
0.444 |
|
| 2017 |
Aguirre AJ, Carter S, Camarda N, Ghazani A, Nowak J, Silva AD, Brais L, Ragon D, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Shyn P, ... ... Garraway LA, et al. Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine Cancer Research. 77: 3036-3036. DOI: 10.1158/1538-7445.Am2017-3036 |
0.635 |
|
| 2017 |
Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Alkhairy S, Oh C, Peng A, Deasy R, Sayeed A, Ronning P, ... ... Garraway L, et al. Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models Cancer Research. 77: 1953-1953. DOI: 10.1158/1538-7445.Am2017-1953 |
0.622 |
|
| 2017 |
Amin-Mansour A, Jané-Valbuena J, Mu XJ, Garraway L. Abstract 1564: A computational framework for removing mouse contamination in tumors sequenced from patient-derived xenografts Cancer Research. 77: 1564-1564. DOI: 10.1158/1538-7445.Am2017-1564 |
0.471 |
|
| 2017 |
Zaidi SH, Sun W, Huyghe J, Grasso CS, Trinh Q, Connolly C, French A, Mu J, Giannakis M, Shinbrot E, Borozan I, Quist MJ, Brenner H, Buchanan D, Campbell P, ... ... Garraway L, et al. Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors Epidemiology. 77: 1286-1286. DOI: 10.1158/1538-7445.Am2017-1286 |
0.364 |
|
| 2017 |
Stover E, Amin-Mansour A, Palakurthi S, Dharma S, Zeng Q, Zhou S, Desai P, Garraway L, Matulonis U, Liu J. Abstract 1010: Genomic analysis of recurrent ovarian cancer in patient-derived xenografts treated with platinum and taxane chemotherapy Cancer Research. 77: 1010-1010. DOI: 10.1158/1538-7445.Am2017-1010 |
0.481 |
|
| 2017 |
Rotem A, Garraway L, Su M, Basu A, Regev A, Struhl K. Miniaturizing 3D assay for high-throughput drug and genetic screens for small patient-derived tumor samples (Conference Presentation) Proceedings of Spie. 10046. DOI: 10.1117/12.2256299 |
0.366 |
|
| 2017 |
Osseiran S, Wang H, Dutton-Regester K, Garraway LA, Evans CL. Label-free longitudinal monitoring of melanogenesis in the evolution of melanoma treatment resistance (Conference Presentation) Proceedings of Spie. 10069. DOI: 10.1117/12.2253399 |
0.356 |
|
| 2017 |
Nishihara R, Chan AT, Mu J, Giannakis M, Mima K, Qian ZR, Bullman S, Kostic A, Huttenhower C, Garrett W, Giovannucci E, Meyerson M, Garraway L, Fuchus C, Ogino S. Whole-exome sequencing analyses of colorectal cancer with Fusobacterium nucleatum The Faseb Journal. 31. DOI: 10.1096/Fasebj.31.1_Supplement.178.12 |
0.382 |
|
| 2017 |
Suarez-Farinas M, Devi K, Dannenfelser R, Izar B, Prakadan S, Zhu Q, Yoon C, Regev A, Garraway L, Shalek A, Troyansakaya O, Anandasabapathy N. 065 Highly conserved tissue immune signatures are co-opted in cancer Journal of Investigative Dermatology. 137: S11. DOI: 10.1016/J.Jid.2017.02.078 |
0.336 |
|
| 2016 |
Tsvetkov P, Sokol E, Jin D, Brune Z, Thiru P, Ghandi M, Garraway LA, Gupta PB, Santagata S, Whitesell L, Lindquist S. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers. Proceedings of the National Academy of Sciences of the United States of America. PMID 28028240 DOI: 10.1073/Pnas.1619067114 |
0.457 |
|
| 2016 |
Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, ... ... Garraway LA, et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. Jci Insight. 1: e87062. PMID 27882345 DOI: 10.1172/Jci.Insight.87062 |
0.514 |
|
| 2016 |
Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, ... ... Garraway LA, et al. Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27797976 DOI: 10.1158/1078-0432.Ccr-16-2154-T |
0.704 |
|
| 2016 |
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, ... ... Garraway LA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports. 17: 1206. PMID 27760322 DOI: 10.1016/J.Celrep.2016.10.009 |
0.56 |
|
| 2016 |
Brenan L, Andreev A, Cohen O, Pantel S, Kamburov A, Cacchiarelli D, Persky NS, Zhu C, Bagul M, Goetz EM, Burgin AB, Garraway LA, Getz G, Mikkelsen TS, Piccioni F, et al. Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. Cell Reports. 17: 1171-1183. PMID 27760319 DOI: 10.1016/J.Celrep.2016.09.061 |
0.413 |
|
| 2016 |
Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, ... ... Garraway LA, et al. High order drug combinations are required to effectively kill colorectal cancer cells. Cancer Research. PMID 27659046 DOI: 10.1158/0008-5472.Can-15-3425 |
0.587 |
|
| 2016 |
Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discovery. PMID 27604488 DOI: 10.1158/2159-8290.Cd-16-0305 |
0.436 |
|
| 2016 |
Izar B, Joyce C, Goff S, Cho NL, Shah PM, Sharma G, Li J, Ibrahim N, Gold J, Hodi FS, Garraway LA, Novina CD, Bertagnolli MM, Yoon CH. Bidirectional Crosstalk Between Patient-Derived Melanoma and Cancer-Associated Fibroblasts Promotes Invasion and Proliferation. Pigment Cell & Melanoma Research. PMID 27482935 DOI: 10.1111/Pcmr.12513 |
0.425 |
|
| 2016 |
Dang M, Henderson RE, Garraway LA, Zon LI. Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. Disease Models & Mechanisms. 9: 811-20. PMID 27482819 DOI: 10.1242/Dmm.024166 |
0.308 |
|
| 2016 |
Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, ... ... Garraway LA, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine. 8: 79. PMID 27460824 DOI: 10.1186/S13073-016-0333-9 |
0.741 |
|
| 2016 |
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, ... ... Garraway L, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. PMID 27433846 DOI: 10.1056/Nejmoa1603144 |
0.614 |
|
| 2016 |
Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 820-4. PMID 27407122 DOI: 10.6004/Jnccn.2016.0086 |
0.592 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Garraway LA, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. 99: 246. PMID 27392080 DOI: 10.1016/J.Ajhg.2016.06.002 |
0.576 |
|
| 2016 |
Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, ... ... Garraway LA, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications. 7: 11987. PMID 27329820 DOI: 10.1038/Ncomms11987 |
0.464 |
|
| 2016 |
Louissaint A, Schafernak KT, Geyer J, Kovach AE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morgan EA, Neuberg DS, South ST, Harris MH, Hasserjian RP, ... ... Garraway LA, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAP kinase pathway mutations. Blood. PMID 27325104 DOI: 10.1182/Blood-2015-12-682591 |
0.403 |
|
| 2016 |
Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. Jama Oncology. PMID 27310333 DOI: 10.1001/Jamaoncol.2016.1056 |
0.51 |
|
| 2016 |
Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, ... ... Garraway LA, et al. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery. PMID 27260156 DOI: 10.1158/2159-8290.Cd-16-0154 |
0.407 |
|
| 2016 |
Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato AC, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, ... ... Garraway LA, et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell. PMID 27238081 DOI: 10.1016/J.Ccell.2016.04.012 |
0.399 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Garraway LA, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. PMID 27181682 DOI: 10.1016/J.Ajhg.2016.04.011 |
0.616 |
|
| 2016 |
Allen EM, Robinson D, Morrissey C, Pritchard C, Imamovic A, Carter S, Rosenberg M, McKenna A, Wu YM, Cao X, Chinnaiyan A, Garraway L, Nelson PS. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: Implications for precision cancer medicine. Oncotarget. PMID 27167109 DOI: 10.18632/Oncotarget.9184 |
0.465 |
|
| 2016 |
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, ... ... Garraway LA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports. PMID 27149842 DOI: 10.1016/J.Celrep.2016.03.075 |
0.659 |
|
| 2016 |
Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, ... ... Garraway LA, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. Jama Oncology. PMID 27124486 DOI: 10.1001/Jamaoncol.2016.0509 |
0.328 |
|
| 2016 |
Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, ... ... Garraway LA, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, N.Y.). 352: 189-196. PMID 27124452 DOI: 10.1126/Science.Aad0501 |
0.594 |
|
| 2016 |
Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, Abazeed ME, Hammerman PS, DiCara D, Konieczkowski DJ, Johannessen CM, Liberzon A, Alizad-Rahvar AR, Alexe G, Aguirre A, ... ... Garraway LA, et al. Characterizing genomic alterations in cancer by complementary functional associations. Nature Biotechnology. PMID 27088724 DOI: 10.1038/Nbt.3527 |
0.742 |
|
| 2016 |
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, ... ... Garraway LA, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). PMID 26940869 DOI: 10.1126/Science.Aaf1490 |
0.612 |
|
| 2016 |
Yu C, Mannan AM, Yvone GM, Ross KN, Zhang YL, Marton MA, Taylor BR, Crenshaw A, Gould JZ, Tamayo P, Weir BA, Tsherniak A, Wong B, Garraway LA, Shamji AF, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nature Biotechnology. PMID 26928769 DOI: 10.1038/Nbt.3460 |
0.39 |
|
| 2016 |
Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, ... ... Garraway LA, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (New York, N.Y.). PMID 26912360 DOI: 10.1126/Science.Aad5214 |
0.509 |
|
| 2016 |
Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, Akdemir KC, Mahdavi M, Peng Q, Chang QE, Hornigold K, Arold ST, Welch HC, Garraway LA, Chin L. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 26884185 DOI: 10.1073/Pnas.1513801113 |
0.412 |
|
| 2016 |
Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, ... ... Garraway L, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26866579 DOI: 10.1038/Gim.2015.207 |
0.723 |
|
| 2016 |
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, ... ... Garraway LA, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine. 22: 298-305. PMID 26855148 DOI: 10.1038/Nm.4045 |
0.636 |
|
| 2016 |
Giannakis M, Mu JX, Shukla S, Qian ZR, Cohen O, Nishihara R, Cao Y, Yamauchi M, Sukawa Y, Nosho K, Ng K, Meyerhardt JA, Lawrence M, Gabriel SB, Lander E, ... ... Garraway LA, et al. Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer. Journal of Clinical Oncology. 34: 557-557. DOI: 10.1200/Jco.2016.34.4_Suppl.557 |
0.458 |
|
| 2016 |
McGraw SA, Joffe S, Garber JE, Janne PA, Lindeman NI, Oliver N, Sholl LM, Allen EMV, Wagle N, Garraway LA, Gray SW. Deliberations of a precision medicine tumor board. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E13005 |
0.67 |
|
| 2016 |
Chalmers ZR, Huang FW, Gay LM, Ali SM, Chmielecki J, Ross JS, Miller VA, Ganesan S, Stephens P, Garraway LA, Frampton GM. Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB. Journal of Clinical Oncology. 34: 9572-9572. DOI: 10.1200/Jco.2016.34.15_Suppl.9572 |
0.497 |
|
| 2016 |
Stover E, Garraway LA, Matulonis UA. Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients. Journal of Clinical Oncology. 34: 5572-5572. DOI: 10.1200/Jco.2016.34.15_Suppl.5572 |
0.416 |
|
| 2016 |
Waks AG, Cohen O, Helvie K, Lloyd MR, Marini L, Oh C, Oliver N, Lindeman NI, Matulonis UA, Krop IE, Garraway LA, Winer EP, Lin NU, Wagle N. Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). Journal of Clinical Oncology. 34: 542-542. DOI: 10.1200/Jco.2016.34.15_Suppl.542 |
0.641 |
|
| 2016 |
Nelson P, Mateo J, Beltran H, De Sarkar N, Elemento O, Rubin MA, Vinson JN, Filipenko J, Robinson DR, Chinnaiyan AM, Van Allen EM, Garofalo A, Taplin M, Garraway LA, Carreira S, et al. Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 34: 5009-5009. DOI: 10.1200/Jco.2016.34.15_Suppl.5009 |
0.428 |
|
| 2016 |
Garofalo A, Sholl LM, Reardon B, Amin-Mansour A, Miao D, Liu D, Oliver N, Ghazani AA, Gray SW, Janne PA, Garber JE, Joffe S, Lindeman NI, Garraway LA, Wagle N, et al. Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. Journal of Clinical Oncology. 34: 1500-1500. DOI: 10.1200/Jco.2016.34.15_Suppl.1500 |
0.662 |
|
| 2016 |
Ghazani AA, Oliver N, Pierre JPS, Garofalo A, Sholl LM, Lindeman NI, Garber JE, Joffe S, Janne PA, Gray SW, Garraway LA, Allen EMV, Wagle N. Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. Journal of Clinical Oncology. 34: 11565-11565. DOI: 10.1200/Jco.2016.34.15_Suppl.11565 |
0.681 |
|
| 2016 |
Wagle N, Helvie K, Lloyd MR, Marini L, Waks AG, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman NI, Krop IE, Garraway LA, et al. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. Journal of Clinical Oncology. 34: 11513-11513. DOI: 10.1200/Jco.2016.34.15_Suppl.11513 |
0.656 |
|
| 2016 |
Izar B, Tirosh I, Prakadan S, Wadsworth M, Rotem A, Trombetta J, Shah P, Dutton-Regester K, Fallahi M, Ren-Lin J, Murphy G, Lian C, Sorger P, Bertagnolli MM, Rozenblatt-Rosen O, ... ... Garraway LA, et al. Implementation of single-cell genomics as a translational tool in patients with metastatic melanoma. Journal of Clinical Oncology. 34: 11503-11503. DOI: 10.1200/Jco.2016.34.15_Suppl.11503 |
0.39 |
|
| 2016 |
Tseng Y, Keskula P, Hong AL, Gill S, Cheah JH, Kryukov GV, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... Garraway L, et al. Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B26 |
0.687 |
|
| 2016 |
Luo F, Le X, Jeselsohn R, Brown M, Garraway L. Abstract P3-05-13: Estrogen-independent growth ofESR1-mutant breast cancer cells requires CDK4/6 Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-13 |
0.427 |
|
| 2016 |
Nguyen M, Buchwalter G, Luo F, Garraway L, Brown M, Jeselsohn R. Abstract P3-05-09: Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-09 |
0.41 |
|
| 2016 |
Hong AL, Cowley GS, Tseng Y, Cheah JH, Jonas O, Doshi MB, Kynnap BD, Oh C, Meyer S, Clemons P, Burger M, Vazquez F, Weir B, Kryukov GV, Church A, ... ... Garraway LA, et al. Abstract B38: Developing a functional genomics platform to interrogate rare pediatric cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B38 |
0.466 |
|
| 2016 |
Aguirre AJ, Shao W, Xu H, Weir B, Vazquez F, Meyers R, Zhang C, Doshi M, Cowley GS, Ewachiw T, Rasheed Z, Golub TR, Stegmaier K, Roberts CW, Garraway LA, et al. Abstract PR05: Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-Pr05 |
0.406 |
|
| 2016 |
Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs M, Moore F, Taylor-Weiner A, Wala J, Zack T, Lee T, Fennessy F, Alexander E, ... ... Garraway L, et al. Abstract LB-227: Truncal activating MAPK and PI3K pathway alterations and exceptional response to dual pathway inhibition in anaplastic thyroid cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-227 |
0.646 |
|
| 2016 |
Adalsteinsson VA, Ha G, Freeman S, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, ... ... Garraway LA, et al. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-136 |
0.713 |
|
| 2016 |
Stover EH, Howitt B, Lindeman NI, Garraway LA, Matulonis UA. Abstract 95: Somatic mutations and copy number variations in cancer-associated genes in 695 ovarian cancer patients Cancer Research. 76: 95-95. DOI: 10.1158/1538-7445.Am2016-95 |
0.536 |
|
| 2016 |
Rotem A, Izar B, Garraway LA. Abstract 600: Melanoma and ovarian cancer cells tested for drug sensitivity using anchorage-independent growth Cancer Research. 76: 600-600. DOI: 10.1158/1538-7445.Am2016-600 |
0.439 |
|
| 2016 |
Zaidi SH, Grasso C, Mu J, Shinbrot E, Giannakis M, Connolly C, Borozan I, Brenner H, Campbell P, Chan A, Chang-Claude J, Du M, Ferretti V, French A, Fuchs C, ... ... Garraway L, et al. Abstract 5221: Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors Cancer Research. 76: 5221-5221. DOI: 10.1158/1538-7445.Am2016-5221 |
0.502 |
|
| 2016 |
Izar B, Tirsh I, Prakadan S, Wadsworth M, Treacy D, Trombetta J, Rotem A, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin J, Jane-Valbuena J, Rozenblatt-Rosen O, Yoon C, ... ... Garraway L, et al. Abstract 4380: Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-sequencing Cancer Research. 76: 4380-4380. DOI: 10.1158/1538-7445.Am2016-4380 |
0.429 |
|
| 2016 |
Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... Garraway L, et al. Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Cancer Research. 76: 4367-4367. DOI: 10.1158/1538-7445.Am2016-4367 |
0.695 |
|
| 2016 |
Chalmers ZR, Huang FW, Ali SM, Yelensky R, Chmielecki J, Ross JS, Miller VA, Stephens PJ, Garraway LA, Frampton GM. Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load Cancer Research. 76: 3576-3576. DOI: 10.1158/1538-7445.Am2016-3576 |
0.498 |
|
| 2016 |
Dutton-Regester K, Garraway L. Abstract 237: Enrichment of AXL-high/ MITF-low melanoma cells in the presence of MAPK inhibitorsin vitro Cancer Research. 76: 237-237. DOI: 10.1158/1538-7445.Am2016-237 |
0.41 |
|
| 2016 |
Goetz E, Rabasha B, Garraway L. Abstract 2150: Alternative treatment strategies to overcome MAPK inhibitor resistance in melanoma Cancer Research. 76: 2150-2150. DOI: 10.1158/1538-7445.Am2016-2150 |
0.36 |
|
| 2016 |
Groner AC, Cato L, Tribolet-Hardy Jd, Bernasocchi T, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Garraway LA, Wild PJ, Theurillat J, Brown M. Abstract 1806: TRIM24 is an oncogenic transcriptional activator in prostate cancer Cancer Research. 76: 1806-1806. DOI: 10.1158/1538-7445.Am2016-1806 |
0.429 |
|
| 2016 |
Grasso CS, Shinbrot E, Yu M, Liesersen M, Chaisson M, Chan A, Connolly C, Dai J, Du M, Fuchs C, Garraway L, Giannakis M, Harrison T, Hsu L, Huyghe J, et al. Abstract 136: Refining the molecular profile of colorectal tumors to expand prevention and treatment opportunities Cancer Research. 76: 136-136. DOI: 10.1158/1538-7445.Am2016-136 |
0.492 |
|
| 2016 |
Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Sellers WR, Schlegel R, Porter D, Morris E, Wuerthner J, Jeay S, Greshock J, ... ... Garraway LA, et al. Abstract 1311: High order drug combinations are required to effectively kill colorectal cancer cells Cancer Research. 76: 1311-1311. DOI: 10.1158/1538-7445.Am2016-1311 |
0.595 |
|
| 2016 |
Kieran MW, Sun Y, Pilarz C, Calligaris D, Chadwick EJ, Alberta JA, Ramkissoon SH, Ramkissoon LA, Garcia VM, Wilkinson K, Kane M, Goumnerova L, Chi SN, Manley P, Wright KD, ... ... Garraway LA, et al. LG-47TYPE II RAF INHIBITORS INHIBIT BRAF MUTATIONS AND TRUNCATED FUSIONS IN PEDIATRIC LOW-GRADE GLIOMAS Neuro-Oncology. 18: iii89.2-iii89. DOI: 10.1093/Neuonc/Now075.47 |
0.568 |
|
| 2016 |
Janouskova H, El Tekle G, Udeshi N, Ulbricht A, Rinaldi A, Civenni G, Catapano C, Peter M, Carr S, Garraway L, Theurillat J. Opposing therapeutic efficacy of BET inhibitors is determined by cancer type-specific SPOP mutants European Journal of Cancer. 69: S2. DOI: 10.1016/S0959-8049(16)32608-9 |
0.385 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Garraway LA, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 162: 454. PMID 28843286 DOI: 10.1016/J.Cell.2015.06.053 |
0.616 |
|
| 2015 |
Huang FW, Bielski CM, Rinne ML, Hahn WC, Sellers WR, Stegmeier F, Garraway LA, Kryukov GV. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 4: e176. PMID 26657580 DOI: 10.1038/oncsis.2015.39 |
0.595 |
|
| 2015 |
Kryukov GV, Bielski C, Samocha K, Fromer M, Seepo S, Gentry C, Neale B, Garraway LA, Sweeney CJ, Taplin ME, Van Allen EM. Genetic effect of chemotherapy exposure in children of testicular cancer survivors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26631610 DOI: 10.1158/1078-0432.Ccr-15-2317 |
0.586 |
|
| 2015 |
Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, ... ... Garraway LA, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer (Oxford, England : 1990). PMID 26608120 DOI: 10.1016/J.Ejca.2015.08.022 |
0.33 |
|
| 2015 |
Stransky N, Ghandi M, Kryukov GV, Garraway LA, Lehár J, Liu M, Sonkin D, Kauffmann A, Venkatesan K, Edelman EJ, Riester M, Barretina J, Caponigro G, Schlegel R, Sellers WR, et al. Pharmacogenomic agreement between two cancer cell line data sets Nature. 528: 84-87. PMID 26570998 DOI: 10.1038/Nature15736 |
0.637 |
|
| 2015 |
Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, ... ... Garraway L, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery. PMID 26410082 DOI: 10.1158/2159-8290.Cd-15-0369 |
0.668 |
|
| 2015 |
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, ... ... Garraway LA, et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science (New York, N.Y.). PMID 26359337 DOI: 10.1126/Science.Aad0095 |
0.616 |
|
| 2015 |
Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA. Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors. Molecular Cancer Therapeutics. PMID 26351322 DOI: 10.1158/1535-7163.Mct-15-0136-T |
0.429 |
|
| 2015 |
Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, ... ... Garraway LA, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. Jama Oncology. PMID 26181352 DOI: 10.1001/Jamaoncol.2015.1377 |
0.324 |
|
| 2015 |
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, ... ... Garraway LA, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Jama Oncology. 1: 238-44. PMID 26181029 DOI: 10.1001/Jamaoncol.2015.34 |
0.673 |
|
| 2015 |
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, ... ... Garraway LA, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunology Research. PMID 26014096 DOI: 10.1158/2326-6066.Cir-15-0024 |
0.58 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, ... ... Garraway LA, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28. PMID 26000489 DOI: 10.1016/J.Cell.2015.05.001 |
0.653 |
|
| 2015 |
Rotem A, Janzer A, Izar B, Ji Z, Doench JG, Garraway LA, Struhl K. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proceedings of the National Academy of Sciences of the United States of America. 112: 5708-13. PMID 25902495 DOI: 10.1073/Pnas.1505979112 |
0.333 |
|
| 2015 |
Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. Cancer Research. 75: 1944-8. PMID 25808865 DOI: 10.1158/0008-5472.Can-14-3602 |
0.639 |
|
| 2015 |
Van Allen EM, Garraway LA, Rosenberg JE. Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014. European Urology. 68: e31-2. PMID 25770487 DOI: 10.1016/j.eururo.2015.02.044 |
0.515 |
|
| 2015 |
Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, ... ... Garraway LA, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 27: 397-408. PMID 25759024 DOI: 10.1016/J.Ccell.2015.02.005 |
0.585 |
|
| 2015 |
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, ... ... Garraway LA, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67. PMID 25673644 DOI: 10.1158/2159-8290.Cd-14-1518 |
0.759 |
|
| 2015 |
Fay AP, Allen EMV, Murray B, Albiges L, Signoretti S, Ho TH, Hakimi AA, Mickey SS, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK. Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). Journal of Clinical Oncology. 33: 422-422. DOI: 10.1200/Jco.2015.33.7_Suppl.422 |
0.366 |
|
| 2015 |
Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Sucker A, Rizos H, Hugo W, Gutzmer R, Kefford R, Gogas H, Kong X, Scolyer RA, Garraway LA, et al. BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. Journal of Clinical Oncology. 33: 9008-9008. DOI: 10.1200/Jco.2015.33.15_Suppl.9008 |
0.386 |
|
| 2015 |
Beltran H, Prandi D, Mosquera JM, Giannopoulou E, Puca L, Marotz C, Nanus DM, Tagawa ST, Elemento O, Allen EMV, Sboner A, Garraway LA, Rubin MA, Demichelis F. Defining a molecular subclass of treatment resistant prostate cancer. Journal of Clinical Oncology. 33: 5004-5004. DOI: 10.1200/Jco.2015.33.15_Suppl.5004 |
0.355 |
|
| 2015 |
Giannakis M, Shukla S, Mu JX, Nishihara R, Yamauchi M, Sukawa Y, Qian ZR, Nosho K, Inamura K, Bahl S, Ng K, Chan AT, Meyerhardt JA, Gabriel SB, Lander E, ... ... Garraway LA, et al. Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. Journal of Clinical Oncology. 33: 3505-3505. DOI: 10.1200/Jco.2015.33.15_Suppl.3505 |
0.418 |
|
| 2015 |
Van Allen EM, Kryukov G, Bielski C, Samocha K, Fromer M, Seepo S, Gentry C, Neale B, Sweeney C, Garraway LA, Taplin M. Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors. Journal of Clinical Oncology. 33: 1543-1543. DOI: 10.1200/Jco.2015.33.15_Suppl.1543 |
0.426 |
|
| 2015 |
Johannessen C, Konieczkowski D, Abudayyeh O, Kim JW, Cooper Z, Piris A, Frederick D, Barzily-Rokni M, Straussman R, Haq R, Fisher D, Mesirov J, Hahn W, Flaherty K, Wargo J, ... ... Garraway L, et al. Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr04 |
0.411 |
|
| 2015 |
Goetz EM, Ghandi M, Treacy D, Wagle N, Garraway LA. Abstract PR02: Identification of ERK1/2 mutations that confer resistance to MAPK pathway inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr02 |
0.617 |
|
| 2015 |
Wong TC, Johannessen CM, Garraway LA. Abstract B33: Integration of genome-wide datasets identifies SOX10 as a lineage-specific genetic dependency in melanoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B33 |
0.505 |
|
| 2015 |
Grabiner B, Wagle N, Allen EV, Garraway L, Lorch J, Sabatini D. Abstract PR04: mTOR mutations in cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Pr04 |
0.696 |
|
| 2015 |
Berger AH, Kim E, Brooks A, Ilic N, Shrestha Y, Tseng Y, Wu X, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Kantoff P, ... ... Garraway LA, et al. Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants Cancer Research. 75: 957-957. DOI: 10.1158/1538-7445.Transcagen-Pr07 |
0.527 |
|
| 2015 |
Place CS, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, ... ... Garraway LA, et al. Abstract A1-15: Systematic genomic characterization of uveal melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-15 |
0.674 |
|
| 2015 |
Giltnane JM, Balko JM, Stricker TL, Young C, Estrada MV, Wagle N, Allen Ev, Mu XJ, Sanchez V, Farley J, Fitzgerald K, Graber A, Pinto JA, Doimi F, Gómez H, ... ... Garraway L, et al. Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-3 |
0.652 |
|
| 2015 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Bose R, Shen W, Wolff AC, ... ... Garraway LA, et al. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-5 |
0.635 |
|
| 2015 |
Corcoran RB, Ahronian LG, Allen EV, Coffee EM, Wagle N, Kwak EL, Faris JE, Iafrate AJ, Garraway LA, Engelman JA. Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ng04 |
0.652 |
|
| 2015 |
Beltran H, Prandi D, Mosquera JM, Giannopoulou E, Puca L, Marotz C, Nanus DM, Tagawa ST, Elemento O, Allen EV, Sboner A, Garraway L, Rubin MA, Demichelis F. Abstract LB-018: Defining a molecular subclass of treatment-resistant prostate cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-018 |
0.362 |
|
| 2015 |
Berger A, Kim E, Brooks A, Shrestha Y, Tseng Y, Wu X, Ilic N, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Doench J, ... ... Garraway L, et al. Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2015-957 |
0.384 |
|
| 2015 |
Amin-Mansour A, Sioletic S, Carter SL, Garraway LA, Demetri GD, George S, Allen EMV, Wagner AJ. Abstract 4819: Differential evolution of tumor heterogeneity in leiomyosarcomas and liposarcomas suggested by genomic profiling Cancer Research. 75: 4819-4819. DOI: 10.1158/1538-7445.Am2015-4819 |
0.463 |
|
| 2015 |
Brastianos PK, Carter SL, Santagata S, Taylor-Weiner A, Jones RT, Allen EV, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Cahill D, Curry WT, Dunn IF, Paek SH, Hummelen PV, ... ... Garraway L, et al. Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations Brain. 75: 4727-4727. DOI: 10.1158/1538-7445.Am2015-4727 |
0.545 |
|
| 2015 |
Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, Farsidjani A, Zubrowski M, Halilovic E, Morris E, Sellers WR, Schlegel R, Wuerthner J, Garraway LA, Jeay S, et al. Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B04 |
0.589 |
|
| 2015 |
Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Lu D, Rotem A, Lian C, Murphy G, Cohen O, Allen Ev, Bertagnolli M, Genshaft A, Hughes TK, ... ... Garraway L, et al. Abstract CN07-04: Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Cn07-04 |
0.408 |
|
| 2015 |
Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA. Abstract C72: Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C72 |
0.456 |
|
| 2015 |
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, ... ... Garraway LA, et al. Genomic Classification of Cutaneous Melanoma Cell. 161: 1681-1696. DOI: 10.1016/j.cell.2015.05.044 |
0.471 |
|
| 2014 |
Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 18661-6. PMID 25512530 DOI: 10.1073/Pnas.1412228112 |
0.362 |
|
| 2014 |
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, ... ... Garraway LA, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: E5564-73. PMID 25512523 DOI: 10.1073/Pnas.1419260111 |
0.835 |
|
| 2014 |
Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, Kotliar D, Zhang W, Ghandi M, Garraway L, Fernandes SM, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 26: 813-25. PMID 25490447 DOI: 10.1016/J.Ccell.2014.10.012 |
0.347 |
|
| 2014 |
Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, ... ... Garraway LA, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nature Genetics. 46: 1264-6. PMID 25344691 DOI: 10.1038/Ng.3127 |
0.625 |
|
| 2014 |
Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Research. 74: 7079-89. PMID 25320010 DOI: 10.1158/0008-5472.Can-14-2073 |
0.606 |
|
| 2014 |
Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, ... ... Garraway LA, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. The New England Journal of Medicine. 371: 1426-33. PMID 25295501 DOI: 10.1056/Nejmoa1403352 |
0.734 |
|
| 2014 |
Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Prive GG, Carr SA, Garraway LA. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science (New York, N.Y.). 346: 85-89. PMID 25278611 DOI: 10.1126/Science.1250255 |
0.727 |
|
| 2014 |
Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera JM, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA, Demichelis F. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biology. 15: 439. PMID 25160065 DOI: 10.1186/S13059-014-0439-6 |
0.755 |
|
| 2014 |
MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. The Journal of Molecular Diagnostics : Jmd. 16: 660-72. PMID 25157968 DOI: 10.1016/J.Jmoldx.2014.06.004 |
0.498 |
|
| 2014 |
Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, ... ... Garraway LA, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 4: 1140-53. PMID 25096233 DOI: 10.1158/2159-8290.Cd-14-0623 |
0.71 |
|
| 2014 |
Choy E, MacConaill LE, Cote GM, Le LP, Shen JK, Nielsen GP, Iafrate AJ, Garraway LA, Hornicek FJ, Duan Z. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. Plos One. 9: e101283. PMID 24983247 DOI: 10.1371/Journal.Pone.0101283 |
0.441 |
|
| 2014 |
Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, ... ... Garraway LA, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology. 32: 644-52. PMID 24952901 DOI: 10.1038/Nbt.2940 |
0.757 |
|
| 2014 |
Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, ... Garraway LA, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Medicine. 3: 835-44. PMID 24846059 DOI: 10.1002/Cam4.262 |
0.422 |
|
| 2014 |
Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, ... ... Garraway LA, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine. 20: 682-8. PMID 24836576 DOI: 10.1038/Nm.3559 |
0.721 |
|
| 2014 |
Garraway LA. A Notch for noncoding RNA in melanoma. The New England Journal of Medicine. 370: 1950-1. PMID 24827041 DOI: 10.1056/Nejmcibr1402173 |
0.302 |
|
| 2014 |
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, ... ... Garraway LA, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discovery. 4: 816-27. PMID 24771846 DOI: 10.1158/2159-8290.Cd-13-0424 |
0.375 |
|
| 2014 |
Pop MS, Stransky N, Garvie CW, Theurillat JP, Hartman EC, Lewis TA, Zhong C, Culyba EK, Lin F, Daniels DS, Pagliarini R, Ronco L, Koehler AN, Garraway LA. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Molecular Cancer Therapeutics. 13: 1492-502. PMID 24737027 DOI: 10.1158/1535-7163.Mct-13-0689 |
0.403 |
|
| 2014 |
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, ... ... Garraway LA, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discovery. 4: 546-53. PMID 24625776 DOI: 10.1158/2159-8290.Cd-13-0353 |
0.719 |
|
| 2014 |
Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CW. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature Medicine. 20: 251-4. PMID 24562383 DOI: 10.1038/Nm.3480 |
0.498 |
|
| 2014 |
Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, Grandis JR. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Molecular Cancer Research : McR. 12: 571-82. PMID 24425785 DOI: 10.1158/1541-7786.Mcr-13-0396 |
0.486 |
|
| 2014 |
Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, ... ... Garraway LA, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 1114-9. PMID 24395800 DOI: 10.1073/Pnas.1319551111 |
0.44 |
|
| 2014 |
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 505: 495-501. PMID 24390350 DOI: 10.1038/Nature12912 |
0.492 |
|
| 2014 |
Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy Prostate Cancer and Prostatic Diseases. 17: 23-27. PMID 24366412 DOI: 10.1038/Pcan.2013.37 |
0.592 |
|
| 2014 |
Polak P, Lawrence MS, Haugen E, Stoletzki N, Stojanov P, Thurman RE, Garraway LA, Mirkin S, Getz G, Stamatoyannopoulos JA, Sunyaev SR. Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. Nature Biotechnology. 32: 71-5. PMID 24336318 DOI: 10.1038/Nbt.2778 |
0.469 |
|
| 2014 |
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, ... ... Garraway LA, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery. 4: 61-8. PMID 24265154 DOI: 10.1158/2159-8290.Cd-13-0631 |
0.713 |
|
| 2014 |
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, Mckenna A, Cibulskis K, Farlow D, ... ... Garraway LA, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discovery. 4: 94-109. PMID 24265153 DOI: 10.1158/2159-8290.Cd-13-0617 |
0.725 |
|
| 2014 |
Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Investigational New Drugs. 32: 178-187. PMID 24242861 DOI: 10.1007/S10637-013-0045-6 |
0.731 |
|
| 2014 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Wolff AC, Gabriel SB, Garraway LA, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal of Clinical Oncology. 32: 536-536. DOI: 10.1200/Jco.2014.32.15_Suppl.536 |
0.671 |
|
| 2014 |
Rosenberg JE, Van Allen EM, Mouw KW, Kim PH, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Iyer G, Signoretti S, Reuter VE, Getz G, Kantoff PW, Bochner BH, Choueiri TK, ... ... Garraway LA, et al. Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Journal of Clinical Oncology. 32: 4510-4510. DOI: 10.1200/Jco.2014.32.15_Suppl.4510 |
0.618 |
|
| 2014 |
Gray SW, Wagle N, Garber JE, Rainville IR, Hiller E, Martins Y, Oliver N, Lowenstein C, Najita JS, VanAllen E, Janne PA, Sholl LM, Lindeman NI, Garraway LA, Joffe S. Cancer patients’ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. Journal of Clinical Oncology. 32: 1535-1535. DOI: 10.1200/Jco.2014.32.15_Suppl.1535 |
0.622 |
|
| 2014 |
Kiezun A, Perry J, Tonzi P, Allen EV, Carter SL, Baca S, Bhatt A, Lawrence M, Walensky L, Wagle N, Mora J, deTorres C, Lavarino C, Velasco-Hidalgo L, Cardenas-Cardos R, ... ... Garraway L, et al. Abstract A41: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A41 |
0.812 |
|
| 2014 |
Helming K, Wang X, Wilson B, Vazquez F, Haswell J, Manchester H, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway L, Hahn W, Roberts C. Abstract LB-126: ARID1B is a specific vulnerability in ARID1A-mutant cancers Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-126 |
0.503 |
|
| 2014 |
Luo F, Garraway L. Abstract 3431: Functional characterization of ARID2 in melanoma and melanocytes Cancer Research. 74: 3431-3431. DOI: 10.1158/1538-7445.Am2014-3431 |
0.453 |
|
| 2014 |
Place CS, Cowley GS, Root DE, Garraway LA. Abstract 3429: Synthetic lethal RNAi screens to nominate potential therapeutic combinations for uveal melanoma Cancer Research. 74: 3429-3429. DOI: 10.1158/1538-7445.Am2014-3429 |
0.458 |
|
| 2014 |
Botta G, Jane-Valbuena J, Wong T, Doench J, Garraway LA. Abstract 3316: Characterizing mechanisms of resistance to androgen deprivation in prostate cancer Cancer Research. 74: 3316-3316. DOI: 10.1158/1538-7445.Am2014-3316 |
0.438 |
|
| 2014 |
Chan HM, Jaffe JD, Wang Y, Zhang J, Huether R, Kryukov GV, Bhang HC, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, McDonald ER, Wei L, Ma J, ... ... Garraway LA, et al. Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL Cancer Research. 74: 2930-2930. DOI: 10.1158/1538-7445.Am2014-2930 |
0.602 |
|
| 2014 |
Pop M, Stransky N, Garvie C, Theurillat J, Lewis T, Zhong C, Culyba E, Lin F, Daniels D, Pagliarini R, Ronco L, Koehler A, Garraway L. Abstract 2519: A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein Cancer Research. 74: 2519-2519. DOI: 10.1158/1538-7445.Am2014-2519 |
0.402 |
|
| 2014 |
Mu XJ, Allen EV, Wagle N, Chong C, Butaney M, Farlow D, Getz G, Jänne PA, Garraway LA. Abstract 2371: Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors Cancer Research. 74: 2371-2371. DOI: 10.1158/1538-7445.Am2014-2371 |
0.652 |
|
| 2014 |
Wagle N, Grabiner BC, Allen EMV, Amin-Mansour A, Carter SC, Gray N, Barletta JA, Swanson SJ, Ruan D, Kwiatkowski DJ, Hanna GJ, Haddad RI, Sabatini D, Janne PA, Garraway LA, et al. Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma Cancer Research. 74: 1724-1724. DOI: 10.1158/1538-7445.Am2014-1724 |
0.684 |
|
| 2014 |
Berg JS, Amendola LM, Eng C, Allen EV, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Erratum: Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the clinical sequencing exploratory research consortium (Genetics in Medicine (2013) 15 (860-867) DOI:10.1038/gim.2013.133) Genetics in Medicine. 16. DOI: 10.1038/Gim.2013.191 |
0.597 |
|
| 2014 |
Corcoran R, Coffee E, van Allen E, Ahronian L, Wagle N, Kwak E, Faris J, Iafrate A, Garraway L, Engelman J. 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations European Journal of Cancer. 50: 141. DOI: 10.1016/S0959-8049(14)70554-4 |
0.609 |
|
| 2014 |
Mouw K, Van Allen E, O’Connor K, Wagle N, Kim P, Al-Ahmadie H, Zhu C, Ostravnaya I, Iyer G, Signoretti S, Reuter V, Getz G, Kantoff P, Bochner B, Choueiri T, ... ... Garraway L, et al. Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S88. DOI: 10.1016/J.Ijrobp.2014.05.481 |
0.622 |
|
| 2013 |
Berg JS, Amendola LM, Eng C, Van Allen E, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 860-7. PMID 24195999 DOI: 10.1038/Gim.2013.133 |
0.701 |
|
| 2013 |
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 504: 138-42. PMID 24185007 DOI: 10.1038/Nature12688 |
0.394 |
|
| 2013 |
Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park SI, Kryukov G, ... Garraway LA, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nature Medicine. 19: 1469-72. PMID 24162815 DOI: 10.1038/Nm.3352 |
0.421 |
|
| 2013 |
Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, Kryukov GV, Bhang HE, Taylor JE, Hu M, Englund NP, Yan F, Wang Z, Robert McDonald E, Wei L, Ma J, ... ... Garraway LA, et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nature Genetics. 45: 1386-91. PMID 24076604 DOI: 10.1038/Ng.2777 |
0.781 |
|
| 2013 |
Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, Hindorff LA, Jarvik G, Karavite D, Lebo M, Plon SE, Van Allen E, Weck KE, White PS, Yang Y. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 824-32. PMID 24071794 DOI: 10.1038/Gim.2013.120 |
0.54 |
|
| 2013 |
Hanna MC, Go C, Roden C, Jones RT, Pochanard P, Javed AY, Javed A, Mondal C, Palescandolo E, Van Hummelen P, Hatton C, Bass AJ, Chun SM, Na DC, Kim TI, ... ... Garraway LA, et al. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. Plos One. 8: e74950. PMID 24066160 DOI: 10.1371/Journal.Pone.0074950 |
0.442 |
|
| 2013 |
Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, ... ... Garraway LA, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 154: 1151-61. PMID 23993102 DOI: 10.1016/J.Cell.2013.08.003 |
0.752 |
|
| 2013 |
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, ... ... Garraway LA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 499: 214-8. PMID 23770567 DOI: 10.1038/Nature12213 |
0.758 |
|
| 2013 |
Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, ... ... Garraway LA, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discovery. 3: 1044-57. PMID 23764425 DOI: 10.1158/2159-8290.Cd-12-0592 |
0.565 |
|
| 2013 |
Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Research. 73: 4840-51. PMID 23737487 DOI: 10.1158/0008-5472.Can-12-4089 |
0.36 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, ... ... Garraway LA, et al. Punctuated evolution of prostate cancer genomes. Cell. 153: 666-77. PMID 23622249 DOI: 10.1016/J.Cell.2013.03.021 |
0.793 |
|
| 2013 |
Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, ... ... Garraway LA, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discovery. 3: 761-9. PMID 23619167 DOI: 10.1158/2159-8290.Cd-13-0103 |
0.482 |
|
| 2013 |
Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1806-14. PMID 23589557 DOI: 10.1200/Jco.2012.46.8934 |
0.493 |
|
| 2013 |
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1803-5. PMID 23589545 DOI: 10.1200/Jco.2013.49.4799 |
0.487 |
|
| 2013 |
Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia (New York, N.Y.). 15: 373-83. PMID 23555183 DOI: 10.1593/Neo.122146 |
0.39 |
|
| 2013 |
Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 153: 17-37. PMID 23540688 DOI: 10.1016/J.Cell.2013.03.002 |
0.523 |
|
| 2013 |
Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proceedings of the National Academy of Sciences of the United States of America. 110: 4321-6. PMID 23447565 DOI: 10.1073/Pnas.1205575110 |
0.421 |
|
| 2013 |
Demichelis F, Garraway LA, Rubin MA. Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. Cancer Cell. 23: 133-5. PMID 23410968 DOI: 10.1016/J.Ccr.2013.01.019 |
0.437 |
|
| 2013 |
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science (New York, N.Y.). 339: 957-9. PMID 23348506 DOI: 10.1126/Science.1229259 |
0.471 |
|
| 2013 |
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discovery. 3: 350-62. PMID 23288408 DOI: 10.1158/2159-8290.Cd-12-0470 |
0.72 |
|
| 2013 |
Shao DD, Tsherniak A, Gopal S, Weir BA, Tamayo P, Stransky N, Schumacher SE, Zack TI, Beroukhim R, Garraway LA, Margolin AA, Root DE, Hahn WC, Mesirov JP. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Research. 23: 665-78. PMID 23269662 DOI: 10.1101/Gr.143586.112 |
0.561 |
|
| 2013 |
Konieczkowski DJ, Garraway LA. Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. Cell Research. 23: 13-4. PMID 22847744 DOI: 10.1038/Cr.2012.115 |
0.429 |
|
| 2013 |
Wagle N, Allen EMV, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, ... ... Garraway LA, et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. Journal of Clinical Oncology. 31: 9015-9015. DOI: 10.1200/Jco.2013.31.15_Suppl.9015 |
0.602 |
|
| 2013 |
Lorch JH, Busaidy N, Ruan DT, Janne PA, Limaye SA, Wirth LJ, Barletta JA, Rabinowits G, Garraway LA, Allen EMV, Wagle N, Hanna GJ, Misiukiewicz K, Suda M, Haddad TC, et al. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). Journal of Clinical Oncology. 31: 6023-6023. DOI: 10.1200/Jco.2013.31.15_Suppl.6023 |
0.541 |
|
| 2013 |
Rollins BJ, MacConaill LE, Wagle N, Garcia E, Kuo FC, Longtine JA, Garber JE, Janeway KA, Fuchs CS, Bertagnolli MM, Soiffer R, Matulonis U, Lin NU, Hahn WC, Garraway LA, et al. PROFILE: Broadly based genomic testing for all patients at a major cancer center. Journal of Clinical Oncology. 31: 1531-1531. DOI: 10.1200/Jco.2013.31.15_Suppl.1531 |
0.656 |
|
| 2013 |
Allen EMV, Wagle N, Carter SL, Sucker A, Farlow DN, Hodis E, Taylor-Weiner A, Berking C, Egberts F, Hassel JC, Gogas H, Gutzmer R, Goldinger SM, Loquai C, Ugurel S, ... ... Garraway LA, et al. The genetic landscape of clinical resistance to RAF inhibition in melanoma. Journal of Clinical Oncology. 31: 11009-11009. DOI: 10.1200/Jco.2013.31.15_Suppl.11009 |
0.64 |
|
| 2013 |
Landau D, Clement K, Boyle P, Ziller M, Stevenson KE, Kotliar D, Saksena G, Eng M, Sougnez C, Zhang W, Ghandi M, Garraway L, Gabriel S, Lander ES, Brown JR, et al. Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution Blood. 122: 596-596. DOI: 10.1182/Blood.V122.21.596.596 |
0.348 |
|
| 2013 |
Jaffe J, Wang Y, Chan H, Zhang J, Huether R, Kryukov G, Taylor J, Hu M, Englund N, Yan F, Wang Z, Wei L, Ma J, Easton J, Sellers WR, ... ... Garraway L, et al. Abstract PR01: Global chromatin profiling identifies NSD2 mutations in pediatric acute lymphoblastic leukemia Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Pr01 |
0.652 |
|
| 2013 |
Rodon J, Juric D, Gonzalez-Angulo A, Bendell J, Berlin J, Bootle D, Gravelin K, Huang A, Derti A, Lehar J, Würthner J, Boehm M, Allen Ev, Wagle N, Garraway LA, et al. Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-65 |
0.678 |
|
| 2013 |
Huang FW, Hodis E, Xu MJ, Kryukov G, Chin L, Garraway LA. Abstract LB-228: The identification of recurrent non-coding mutations in melanoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-228 |
0.471 |
|
| 2013 |
Hummelen PV, Ducar M, Jones RT, Raza A, Sunkavalli A, Hanna M, Mills A, Adusumilli R, Kumar P, Schubert L, Breneiser M, Cooley AC, Garcia E, Scholl LM, Lindeman NI, ... ... Garraway L, et al. Abstract 819: Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. Cancer Research. 73: 819-819. DOI: 10.1158/1538-7445.Am2013-819 |
0.702 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, ... ... Garraway LA, et al. Abstract 4601: Punctuated evolution of prostate cancer genomes. Cancer Research. 73: 4601-4601. DOI: 10.1158/1538-7445.Am2013-4601 |
0.751 |
|
| 2013 |
Lui VW, Allen EV, Li H, Zhang F, Zeng Y, Johnson JT, Garraway LA, Mills GB, Grandis JR. Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. Cancer Research. 73: 4565-4565. DOI: 10.1158/1538-7445.Am2013-4565 |
0.504 |
|
| 2013 |
Prandi D, Baca SC, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Allen EV, Kryukov GV, Theurillat J, Soong TD, Nickerson E, Auclair D, ... ... Garraway LA, et al. Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. Cancer Research. 73: 4017-4017. DOI: 10.1158/1538-7445.Am2013-4017 |
0.769 |
|
| 2013 |
Wagle N, Allen EV, Perrin D, Friedrich D, Fisher S, Kryukov G, Ambrogio L, Auclair D, Gray S, Joffe S, Janne P, Garber J, Macconaill L, Lindeman N, Rollins B, ... ... Garraway LA, et al. Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. Cancer Research. 73: 3152-3152. DOI: 10.1158/1538-7445.Am2013-3152 |
0.671 |
|
| 2013 |
Allen EMV, Wagle N, Keizun A, Kryukov G, McKenna A, Huang F, Hiller E, Rainville I, Auclair D, Ambrogio L, Gray S, Joffe S, Getz G, Garber J, Garraway L. Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. Cancer Research. 73: 2570-2570. DOI: 10.1158/1538-7445.Am2013-2570 |
0.679 |
|
| 2013 |
Hedberg ML, Lui V, Li H, Vangara B, Pendleton K, Zeng Y, Gilbert B, Freilino M, Sauerwein S, Peyser N, Diergaarde B, Hammerman P, Garraway L, Mills G, Grandis J. Abstract 2011: The PI3K pathway is the most frequently mutated mitogenic pathway in HNSCC. Cancer Research. 73: 2011-2011. DOI: 10.1158/1538-7445.Am2013-2011 |
0.481 |
|
| 2013 |
Min C, Konieczkowski DJ, Kwon C, Linja M, Vasudevan K, Weir B, Goetz E, Garraway L. Abstract C221: A genome-wide RNA interference screen identifies synthetic lethal interactions with the BRAF oncogene. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C221 |
0.513 |
|
| 2013 |
Whittaker SR, Luo F, Hsiao J, Cowley GS, Root DE, Garraway LA. Abstract B108: A genome-scale shRNA synthetic lethal screen identifies enhancers of sensitivity to RAF inhibition. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B108 |
0.476 |
|
| 2013 |
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Flaherty KT, Wargo JA, Root DE, Garraway LA. Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr10 |
0.384 |
|
| 2013 |
Whittaker SR, Luo F, Hsiao J, Cowley GS, Root DE, Garraway LA. Abstract B27: Probing synthetic lethal interactions with RAF inhibition in BRAF-mutant colorectal cancer Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-B27 |
0.48 |
|
| 2013 |
Horn T, Zhang X, Ho S, Garraway L, Schlegel R, Caponigro G, Lehar J. Abstract B18: High-dimensional combinations of cancer drugs to induce synthetic lethality in colorectal cancer Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-B18 |
0.448 |
|
| 2013 |
Barbieri C, Blattner M, Xu L, Demichelis F, Baca S, Lawrence M, Boysen G, Theurillat J, Tewari A, Zhou P, Garraway L, Rubin M. 200 DEFINING THE MECHANISTIC BASIS OF SPOP MUTATIONS IN PROSTATE CANCER Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1580 |
0.719 |
|
| 2012 |
Gray SW, Hicks-Courant K, Lathan CS, Garraway L, Park ER, Weeks JC. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. Journal of Oncology Practice / American Society of Clinical Oncology. 8: 329-35, 2 p followin. PMID 23598841 DOI: 10.1200/Jop.2012.000626 |
0.387 |
|
| 2012 |
Kieran MW, Roberts CW, Chi SN, Ligon KL, Rich BE, Macconaill LE, Garraway LA, Biegel JA. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood & Cancer. 59: 1155-7. PMID 22997201 DOI: 10.1002/Pbc.24315 |
0.46 |
|
| 2012 |
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, ... ... Garraway LA, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150: 1107-20. PMID 22980975 DOI: 10.1016/J.Cell.2012.08.029 |
0.414 |
|
| 2012 |
Daniels AB, Lee JE, MacConaill LE, Palescandolo E, Van Hummelen P, Adams SM, DeAngelis MM, Hahn WC, Gragoudas ES, Harbour JW, Garraway LA, Kim IK. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. Investigative Ophthalmology & Visual Science. 53: 6991-6. PMID 22977135 DOI: 10.1167/Iovs.12-10427 |
0.393 |
|
| 2012 |
Garraway LA, Baselga J. Whole-genome sequencing and cancer therapy: is too much ever enough? Cancer Discovery. 2: 766-8. PMID 22969114 DOI: 10.1158/2159-8290.Cd-12-0359 |
0.438 |
|
| 2012 |
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, ... ... Garraway LA, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discovery. 2: 934-47. PMID 22961667 DOI: 10.1158/2159-8290.Cd-12-0103 |
0.344 |
|
| 2012 |
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Molecular Cancer Therapeutics. 11: 2301-5. PMID 22879364 DOI: 10.1158/1535-7163.Mct-12-0511 |
0.645 |
|
| 2012 |
Garraway LA. Concordance and discordance in tumor genomic profiling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2937-9. PMID 22826272 DOI: 10.1200/Jco.2011.41.3138 |
0.514 |
|
| 2012 |
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, ... ... Garraway LA, et al. A landscape of driver mutations in melanoma. Cell. 150: 251-63. PMID 22817889 DOI: 10.1016/J.Cell.2012.06.024 |
0.622 |
|
| 2012 |
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, ... ... Garraway LA, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486: 405-9. PMID 22722202 DOI: 10.1038/Nature11154 |
0.629 |
|
| 2012 |
Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes & Development. 26: 1131-55. PMID 22661227 DOI: 10.1101/Gad.191999.112 |
0.416 |
|
| 2012 |
Baca SC, Garraway LA. The genomic landscape of prostate cancer. Frontiers in Endocrinology. 3: 69. PMID 22649426 DOI: 10.3389/Fendo.2012.00069 |
0.754 |
|
| 2012 |
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, ... ... Garraway LA, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 485: 502-6. PMID 22622578 DOI: 10.1038/Nature11071 |
0.79 |
|
| 2012 |
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, ... ... Garraway LA, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics. 44: 685-9. PMID 22610119 DOI: 10.1038/Ng.2279 |
0.788 |
|
| 2012 |
Wood KC, Konieczkowski DJ, Johannessen CM, Boehm JS, Tamayo P, Botvinnik OB, Mesirov JP, Hahn WC, Root DE, Garraway LA, Sabatini DM. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Science Signaling. 5: rs4. PMID 22589389 DOI: 10.1126/Scisignal.2002612 |
0.371 |
|
| 2012 |
Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discovery. 2: 214-26. PMID 22585993 DOI: 10.1158/2159-8290.Cd-12-0012 |
0.354 |
|
| 2012 |
Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery. 2: 82-93. PMID 22585170 DOI: 10.1158/2159-8290.CD-11-0184 |
0.651 |
|
| 2012 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Garraway LA, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483: 603-7. PMID 22460905 DOI: 10.1038/Nature11003 |
0.786 |
|
| 2012 |
Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, ... ... Garraway LA, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 316-21. PMID 22067401 DOI: 10.1200/Jco.2011.36.7680 |
0.396 |
|
| 2012 |
Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, Duan Z. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. 118: 2905-14. PMID 22006429 DOI: 10.1002/Cncr.26617 |
0.376 |
|
| 2012 |
Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, et al. Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. The Journal of Investigative Dermatology. 132: 188-97. PMID 21881587 DOI: 10.1038/Jid.2011.254 |
0.351 |
|
| 2012 |
Allen EMV, Wagle N, Kryukov G, Ramos A, Getz G, Garraway LA. A heuristic platform for clinical interpretation of cancer genome sequencing data. Journal of Clinical Oncology. 30: 10502-10502. DOI: 10.1200/Jco.2012.30.15_Suppl.10502 |
0.653 |
|
| 2012 |
Barbieri CE, Baca SC, Lawrence MS, Getz G, Rubin MA, Garraway LA. Abstract IA13: Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-Ia13 |
0.341 |
|
| 2012 |
Stransky N, Kryukov GV, Caponigro G, Barretina J, Venkatesan K, Margolin AA, Wilson CJ, Lehar J, Jones MD, Palescandolo E, Sougnez C, Onofrio RC, MacConaill L, Ardlie K, Golub TR, ... ... Garraway LA, et al. Abstract 5114: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity Cancer Research. 72: 5114-5114. DOI: 10.1158/1538-7445.Am2012-5114 |
0.503 |
|
| 2012 |
Hodis E, Watson I, Theurillat J, Zou L, Place C, Nickerson E, Auclair D, Cibulskis K, Sivachenko A, Kryukov G, Stransky N, Ramos AH, Voet D, Lawrence MS, Stojanov P, ... ... Garraway LA, et al. Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs Cancer Research. 72: 5056-5056. DOI: 10.1158/1538-7445.Am2012-5056 |
0.49 |
|
| 2012 |
Hatton C, Niu L, Davis M, Mondal C, Luongo L, Go C, Jones RT, Roden C, Palescandolo E, Hummelen PV, Garraway LA, Meyerson M, Hahn W, MacConaill LE. Abstract 3965: An algorithm to detect somatic mutations in cancer specimens using mass spectrometric genotyping Cancer Research. 72: 3965-3965. DOI: 10.1158/1538-7445.Am2012-3965 |
0.422 |
|
| 2012 |
Antony R, Emery C, Garraway LA. Abstract 2953: Anticipating new biochemical mechanisms of resistance to Raf inhibition in Melanoma Cancer Research. 72: 2953-2953. DOI: 10.1158/1538-7445.Am2012-2953 |
0.409 |
|
| 2012 |
Johannessen CM, Johnson LA, Lam D, Hamm L, Piccioni F, Root D, Garraway L. Abstract PR5: Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-Pr5 |
0.411 |
|
| 2012 |
Whittaker S, Hodis E, Wagle N, Hsiao J, Cowley G, Root D, Garraway L. Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B20 |
0.645 |
|
| 2012 |
Banerji S, Cibulskis K, Rangel-Escareño C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, ... ... Garraway LA, et al. Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-Pl07-01 |
0.633 |
|
| 2012 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, J.Wilson C, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, ... ... Garraway LA, et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature. DOI: 10.1038/nature11735 |
0.517 |
|
| 2012 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S, Wilson C, Lehar J, Kryukov G, Murray L, Morrissey M, Sellers W, Schlegel R, Garraway L. 22 The Cancer Cell Line Encyclopedia - Using Preclinical Models to Predict Anticancer Drug Sensitivity European Journal of Cancer. 48: S5-S6. DOI: 10.1016/S0959-8049(12)70726-8 |
0.569 |
|
| 2012 |
Barbieri C, Baca S, Demichelis F, Lawrence M, Blattner M, Theurillat J, Boysen G, Stojanov P, Van Allen E, Stransky N, Nickerson E, Park K, Kitabayashi N, MacDonald T, Vuong T, ... ... Garraway LA, et al. 1314 RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1661 |
0.716 |
|
| 2011 |
Wagle N, Berger MF, Davis MJ, Blumenstiel B, DeFelice M, Hahn WC, Meyerson M, Gabriel SB, MacConaill LE, Garraway LA. Tumor genomic profiling of FFPE samples by massively parallel sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10502. PMID 28022364 DOI: 10.1200/Jco.2011.29.15_Suppl.10502 |
0.625 |
|
| 2011 |
Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, ... ... Garraway LA, et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics. 43: 964-8. PMID 21892161 DOI: 10.1038/Ng.936 |
0.804 |
|
| 2011 |
Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M, Sav A, Longtine JA, Lindeman NI, Garraway LA, Ligon AH, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. The Journal of Molecular Diagnostics : Jmd. 13: 669-77. PMID 21884820 DOI: 10.1016/J.Jmoldx.2011.07.002 |
0.422 |
|
| 2011 |
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, ... ... Garraway LA, et al. The mutational landscape of head and neck squamous cell carcinoma. Science (New York, N.Y.). 333: 1157-60. PMID 21798893 DOI: 10.1126/Science.1208130 |
0.413 |
|
| 2011 |
Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes & Development. 25: 1470-5. PMID 21764851 DOI: 10.1101/Gad.2046711 |
0.777 |
|
| 2011 |
Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, Sethumadhavan S, Woo HK, Jang HG, Jha AK, Chen WW, Barrett FG, Stransky N, Tsun ZY, Cowley GS, ... ... Garraway LA, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 476: 346-50. PMID 21760589 DOI: 10.1038/Nature10350 |
0.724 |
|
| 2011 |
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, ... ... Garraway LA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 108: 12372-7. PMID 21746896 DOI: 10.1073/Pnas.1109363108 |
0.755 |
|
| 2011 |
Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, ... ... Garraway LA, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 471: 513-7. PMID 21430779 DOI: 10.1038/Nature09806 |
0.57 |
|
| 2011 |
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, ... ... Garraway LA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 471: 467-72. PMID 21430775 DOI: 10.1038/Nature09837 |
0.493 |
|
| 2011 |
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3085-96. PMID 21383288 DOI: 10.1200/Jco.2010.33.2312 |
0.669 |
|
| 2011 |
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, ... ... Garraway LA, et al. The genomic complexity of primary human prostate cancer. Nature. 470: 214-20. PMID 21307934 DOI: 10.1038/Nature09744 |
0.409 |
|
| 2011 |
Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood. 117: 2433-40. PMID 21209378 DOI: 10.1182/Blood-2010-09-305128 |
0.38 |
|
| 2011 |
Akavia UD, Litvin O, Sanchez-Garcia F, Kotliar HCD, Kim J, Garraway LA, Pe'er D. Abstract SY17-02: A systems approach to understanding tumor specific drug response Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy17-02 |
0.499 |
|
| 2011 |
Rickman DS, Soong TD, Moss B, Kitabayashi N, Bunting K, Naseeruddin S, Garraway LA, Berger MF, Melnick A, Elemento O, Rubin MA. Abstract LB-249: Oncogene-mediated alterations in chromatin conformation Cancer Research. 71: 2222-2222. DOI: 10.1158/1538-7445.Am2011-Lb-249 |
0.397 |
|
| 2011 |
Barbieri CE, Demichelis F, Grasso C, Vuong T, MacDonald T, Boysen G, Banerjee S, Kitabayashi N, Berger MF, Tewari AK, Garraway LA, Chinnaiyan AM, Rubin MA. Abstract LB-246: Recurrent inactivating mutations in SPOP define a molecular subset of prostate cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-246 |
0.472 |
|
| 2011 |
Kryukov GV, Berger MF, Stransky N, Barretina J, Onofrio R, Caponigro G, Sougnez C, Monahan J, Shefler E, Venkhatesan K, Cibulskis K, Morais P, Sivachenko A, Meltzer J, Lawrence M, ... ... Garraway LA, et al. Abstract 923: Separating the wheat from the chaff: A first look at the Cancer Cell Lines Encyclopedia sequencing data Cancer Research. 71: 923-923. DOI: 10.1158/1538-7445.Am2011-923 |
0.683 |
|
| 2011 |
Barretina J, Stransky N, Caponigro G, Kim S, Margolin A, Venkhatesan K, Kryukov G, Berger M, Monahan J, Morais P, Meltzer J, Mahan S, Sonkin D, Raman P, Jones M, ... ... Garraway L, et al. Abstract 5455: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity Cancer Research. 71: 5455-5455. DOI: 10.1158/1538-7445.Am2011-5455 |
0.669 |
|
| 2011 |
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling Cancer Research. 71: 3933-3933. DOI: 10.1158/1538-7445.Am2011-3933 |
0.684 |
|
| 2011 |
Stransky N, Egloff AM, Tward A, Auclair D, Cibulskis K, Lawrence M, Sivachenko A, Berger M, Seethala R, Sougnez C, Cortes M, Winckler W, Gabriel S, Getz G, Golub T, ... ... Garraway L, et al. Abstract 3931: Whole genome and whole exome sequencing of head and neck cancer Cancer Research. 71: 3931-3931. DOI: 10.1158/1538-7445.Am2011-3931 |
0.535 |
|
| 2011 |
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, ... ... Garraway LA, et al. Abstract 3925: Characterization of complex chromosomal aberrations in prostate cancer from whole genome sequencing Cancer Research. 71: 3925-3925. DOI: 10.1158/1538-7445.Am2011-3925 |
0.476 |
|
| 2011 |
Wei G, Margolin A, Brown E, Cucolo L, Stransky N, Barretina J, Garraway L, Beroukhim R. Abstract 13: Chemical genomics identifies MCL1 repressors and resistance mechanism Cancer Research. 71: 13-13. DOI: 10.1158/1538-7445.Am2011-13 |
0.625 |
|
| 2011 |
Miller T, Fox E, Balko J, Meszoely I, Sanders M, Kuba M, Wagle N, Garraway L, Maira S, Arteaga C. S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S3-4 |
0.604 |
|
| 2011 |
Barbieri C, Boysen G, Demichelis F, Vuong T, Berger M, Kitabayashi N, Tewari A, Grasso C, Chinnaiyan A, Garraway L, Rubin M. 608 COMBINING DNA-SEQ AND RNA-SEQ FOR DISCOVERY OF NOVEL MUTATIONS IN HUMAN PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1461 |
0.319 |
|
| 2010 |
Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D. An integrated approach to uncover drivers of cancer. Cell. 143: 1005-17. PMID 21129771 DOI: 10.1016/J.Cell.2010.11.013 |
0.494 |
|
| 2010 |
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, ... ... Garraway LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468: 968-72. PMID 21107320 DOI: 10.1038/Nature09627 |
0.753 |
|
| 2010 |
MacConaill LE, Garraway LA. Clinical Implications of the Cancer Genome Journal of Clinical Oncology. 28: 5219-5228. PMID 20975063 DOI: 10.1200/Jco.2009.27.4944 |
0.487 |
|
| 2010 |
Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, ... ... Garraway LA, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics. 42: 715-21. PMID 20601955 DOI: 10.1038/Ng.619 |
0.828 |
|
| 2010 |
Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Current Topics in Microbiology and Immunology. 347: 105-33. PMID 20549472 DOI: 10.1007/82_2010_66 |
0.303 |
|
| 2010 |
Garraway LA, Hahn WC. On or off target: mutations, models, and predictions. Science Translational Medicine. 2: 35ps28. PMID 20538617 DOI: 10.1126/Scitranslmed.3001263 |
0.366 |
|
| 2010 |
Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 116: 1919-23. PMID 20519626 DOI: 10.1182/Blood-2010-04-279083 |
0.418 |
|
| 2010 |
Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, Warren R, Bild A, Collins-Brennan D, Hahn H, Harkin DP, Kennedy R, Ilyas M, Morreau H, Proutski V, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. The Oncologist. 15: 390-404. PMID 20350999 DOI: 10.1634/Theoncologist.2009-0233 |
0.408 |
|
| 2010 |
Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, Johnson LA, Robinson J, Verhaak RG, Sougnez C, Onofrio RC, Ziaugra L, Cibulskis K, Laine E, Barretina J, ... ... Garraway LA, et al. Integrative analysis of the melanoma transcriptome. Genome Research. 20: 413-27. PMID 20179022 DOI: 10.1101/Gr.103697.109 |
0.749 |
|
| 2010 |
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, ... ... Garraway LA, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 463: 899-905. PMID 20164920 DOI: 10.1038/Nature08822 |
0.826 |
|
| 2010 |
Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA. An oncogenic role for ETV1 in melanoma. Cancer Research. 70: 2075-84. PMID 20160028 DOI: 10.1158/0008-5472.Can-09-3092 |
0.608 |
|
| 2010 |
Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Molecular Cancer Therapeutics. 9: 257-67. PMID 20124458 DOI: 10.1158/1535-7163.Mct-09-0743 |
0.438 |
|
| 2010 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Garraway LA, et al. Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples Plos One. 5. DOI: 10.1371/Annotation/3A0C8Fee-57Ef-43Ed-B6C2-55B503E6Db5E |
0.416 |
|
| 2010 |
Venkatesan K, Stransky N, Margolin A, Reddy A, Raman P, Sonkin D, Jones M, Wilson C, Kim S, Warmuth M, Sellers W, Lehar J, Barretina J, Caponigro G, Garraway L, et al. Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/Diag-10-Pr2 |
0.624 |
|
| 2010 |
Wagle N, Davis M, Berger MF, Blumenstiel B, Defelice M, Hahn W, Meyerson M, Gabriel SB, MacConaill L, Garraway LA. Abstract LB-122: High-throughput tumor genomic profiling by massively parallel sequencing Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-122 |
0.699 |
|
| 2010 |
Johannessen CM, Wardwell L, Kim SY, Boehm J, Thomas S, Johnson LA, Hieronymus H, Salehi-Ashtiani K, Hill DE, Zhao JJ, Vidal M, Golub TR, Hahn WC, Garraway LA. Abstract 5769: A novel, high-throughput approach to discovering drug-resistance genes identifies CRAF, CrkL, and TPL2/COT as drivers of resistance to BRAFV600E inhibition Cancer Research. 70: 5769-5769. DOI: 10.1158/1538-7445.Am10-5769 |
0.39 |
|
| 2010 |
Beroukhim R, Meyerson M, Garraway L, Prensner J. Abstract 5759: The landscape of copy-number changes across multiple human cancer types Cancer Research. 70: 5759-5759. DOI: 10.1158/1538-7445.Am10-5759 |
0.615 |
|
| 2010 |
Pop M, Doug K, Bradner J, Koehler A, Garraway L. Abstract 3693: Small molecule microarray screens for inhibitors of oncogenic ETS factors Cancer Research. 70: 3693-3693. DOI: 10.1158/1538-7445.Am10-3693 |
0.355 |
|
| 2010 |
Jane-Valbuena J, Widlund H, Perner S, Johnson L, Dibner A, Lin W, Baker A, Nazarian R, Vijayendran K, Sellers W, Hahn W, Duncan L, Rubin M, Fisher D, Garraway LA. Abstract 3111: The ETS factor ETV1 is an oncogene in melanoma Cancer Research. 70: 3111-3111. DOI: 10.1158/1538-7445.Am10-3111 |
0.624 |
|
| 2010 |
Barretina J, Caponigro G, Kim S, Stransky N, Venkhatesan K, Reddy V, Berger M, Morrissey M, Morais P, Meltzer J, Thibault J, Mahan S, Sonkin D, Che J, Raman P, ... ... Garraway L, et al. Abstract 2620: The Cancer Cell Line Encyclopedia project: From integrative cancer genomics to personalized cancer therapy Cancer Research. 70: 2620-2620. DOI: 10.1158/1538-7445.Am10-2620 |
0.704 |
|
| 2010 |
Berger MF, Lawrence MS, Cibulskis K, Pflueger D, Demichelis F, Sougnez C, Onofrio RC, Ambrogio L, Fennell T, Parkin M, Carter SL, Saksena G, Sivachenko A, Voet D, Wilkinson J, ... ... Garraway LA, et al. Abstract 1139: Complete characterization of prostate cancer genomes by massively parallel sequencing Cancer Research. 70: 1139-1139. DOI: 10.1158/1538-7445.Am10-1139 |
0.508 |
|
| 2010 |
Stransky N, Venkhatesan K, Morrissey M, Barretina J, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, Sougnez C, Winckler W, ... ... Garraway L, et al. Abstract 105: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Cancer Research. 70: 105-105. DOI: 10.1158/1538-7445.Am10-105 |
0.669 |
|
| 2010 |
Stransky N, Venkatesan K, Barretina J, Caponigro G, Margolin A, Morrissey M, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, ... ... Garraway L, et al. Abstract PR4: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr4 |
0.65 |
|
| 2009 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Garraway LA, et al. Profiling critical cancer gene mutations in clinical tumor samples. Plos One. 4: e7887. PMID 19924296 DOI: 10.1371/Journal.Pone.0007887 |
0.471 |
|
| 2009 |
Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, ... Garraway LA, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America. 106: 20411-6. PMID 19915144 DOI: 10.1073/Pnas.0905833106 |
0.61 |
|
| 2009 |
Levin JZ, Berger MF, Adiconis X, Rogov P, Melnikov A, Fennell T, Nusbaum C, Garraway LA, Gnirke A. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts Genome Biology. 10: 1-8. PMID 19835606 DOI: 10.1186/Gb-2009-10-10-R115 |
0.405 |
|
| 2009 |
Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, Guerrero S, Lin WM, Pham T, Modrusan Z, Seshagiri S, Stern HM, Waring P, Garraway LA, Chant J, et al. Oncogenic activating mutations are associated with local copy gain. Molecular Cancer Research : McR. 7: 1244-52. PMID 19671679 DOI: 10.1158/1541-7786.Mcr-08-0532 |
0.442 |
|
| 2009 |
Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR. p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Molecular and Cellular Biology. 29: 5377-88. PMID 19635806 DOI: 10.1128/Mcb.01649-08 |
0.55 |
|
| 2009 |
Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, ... ... Garraway LA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 16: 21-32. PMID 19573809 DOI: 10.1016/J.Ccr.2009.04.012 |
0.654 |
|
| 2009 |
Berger MF, Garraway LA. Applications of Genomics in Melanoma Oncogene Discovery Hematology-Oncology Clinics of North America. 23: 397-414. PMID 19464593 DOI: 10.1016/J.Hoc.2009.03.005 |
0.419 |
|
| 2009 |
Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stückrath I, ... ... Garraway LA, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. The Journal of Clinical Investigation. 119: 1727-40. PMID 19451690 DOI: 10.1172/Jci37127 |
0.835 |
|
| 2009 |
Nare B, Garraway LA, Vickers TJ, Beverley SM. PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major. Current Genetics. 55: 287-99. PMID 19396443 DOI: 10.1007/S00294-009-0244-Z |
0.492 |
|
| 2009 |
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, ... ... Garraway LA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research. 69: 3256-61. PMID 19351834 DOI: 10.1158/0008-5472.Can-08-4055 |
0.389 |
|
| 2009 |
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, ... ... Garraway LA, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 106: 4834-9. PMID 19261849 DOI: 10.1073/Pnas.0806514106 |
0.704 |
|
| 2009 |
Linja M, Garraway LA. Stepping on the GAS: a brake pedal for melanoma metastasis? Pigment Cell & Melanoma Research. 22: 8-9. PMID 19154234 DOI: 10.1111/J.1755-148X.2008.00533.X |
0.431 |
|
| 2009 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Garraway LA, et al. Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples Plos One. 4. DOI: 10.1371/annotation/613c7509-e4c9-42ac-82fb-fc504400d9e0 |
0.363 |
|
| 2009 |
Akavia U, Litvin O, Kim J, Mozes E, Kotliar D, Tzur Y, Garraway L, Pe'er D. Abstract B70: Conexic: A Bayesian framework to detect drivers and their function uncovers an endosomal signature in melanoma Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-B70 |
0.481 |
|
| 2009 |
Boehm JS, Cowley G, Weir B, Barretina J, Luo B, Cheung HW, Rusin S, Scott J, Derr A, Tsherniak A, Gopalakrishnan S, Tamayo P, Barbie D, Yang X, Piqani B, ... ... Garraway L, et al. Abstract A23: An integrated platform for the functional annotation of the cancer genome Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A23 |
0.511 |
|
| 2008 |
Li C, Beroukhim R, Weir BA, Winckler W, Garraway LA, Sellers WR, Meyerson M. Major copy proportion analysis of tumor samples using SNP arrays. Bmc Bioinformatics. 9: 204. PMID 18426588 DOI: 10.1186/1471-2105-9-204 |
0.66 |
|
| 2008 |
Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Research. 36: 2446-56. PMID 18304946 DOI: 10.1093/Nar/Gkn089 |
0.664 |
|
| 2008 |
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, ... ... Garraway LA, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research. 68: 664-73. PMID 18245465 DOI: 10.1158/0008-5472.Can-07-2615 |
0.713 |
|
| 2007 |
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Garraway LA, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/Pnas.0710052104 |
0.804 |
|
| 2007 |
Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, ... ... Garraway LA, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 450: 893-8. PMID 17982442 DOI: 10.1038/Nature06358 |
0.724 |
|
| 2007 |
Hill AD, Chang BS, Hill RS, Garraway LA, Bodell A, Sellers WR, Walsh CA. A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome. American Journal of Medical Genetics. Part A. 143: 1692-8. PMID 17603806 DOI: 10.1002/Ajmg.A.31776 |
0.481 |
|
| 2007 |
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129: 1065-79. PMID 17574021 DOI: 10.1016/J.Cell.2007.03.052 |
0.457 |
|
| 2007 |
Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, ... Garraway LA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Research. 67: 4933-9. PMID 17510423 DOI: 10.1158/0008-5472.Can-06-4592 |
0.418 |
|
| 2007 |
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Garraway LA, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975 |
0.818 |
|
| 2007 |
Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, et al. Correction: Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays Plos Computational Biology. 3: e40. DOI: 10.1371/Journal.Pcbi.0030040 |
0.626 |
|
| 2007 |
Garraway LA, Sellers WR. The authors reply [2] Nature Reviews Cancer. 7: 1P. DOI: 10.1038/Nrc1947-C2 |
0.498 |
|
| 2007 |
Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, ... ... Garraway LA, et al. Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer Nature Genetics. 39: 567-567. DOI: 10.1038/Ng0407-567A |
0.704 |
|
| 2006 |
Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era Genes & Development. 20: 2149-2182. PMID 16912270 DOI: 10.1101/Gad.1437206 |
0.422 |
|
| 2006 |
Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nature Reviews. Cancer. 6: 593-602. PMID 16862190 DOI: 10.1038/Nrc1947 |
0.607 |
|
| 2006 |
Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Medicine. 12: 852-5. PMID 16799556 DOI: 10.1038/Nm1437 |
0.652 |
|
| 2006 |
Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Research. 66: 5723-8. PMID 16740710 DOI: 10.1158/0008-5472.Can-05-3928 |
0.377 |
|
| 2006 |
Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson M, Wong WH, Sellers WR, et al. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. Plos Computational Biology. 2: e41. PMID 16699594 DOI: 10.1371/Journal.Pcbi.0020041 |
0.661 |
|
| 2006 |
Garraway LA, Sellers WR. From integrated genomics to tumor lineage dependency. Cancer Research. 66: 2506-8. PMID 16510564 DOI: 10.1158/0008-5472.Can-05-4604 |
0.667 |
|
| 2006 |
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 439: 358-62. PMID 16273091 DOI: 10.1038/Nature04304 |
0.565 |
|
| 2006 |
Garraway LA, Sellers WR. Erratum: Lineage dependency and lineage-survival oncogenes in human cancer Nature Reviews Cancer. 6: 742-742. DOI: 10.1038/Nrc1972 |
0.583 |
|
| 2006 |
Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, et al. Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (Nature Medicine (2006) 12 (852-855)) Nature Medicine. 12. DOI: 10.1038/Nm1006-1220A |
0.616 |
|
| 2005 |
Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harbor Symposia On Quantitative Biology. 70: 25-34. PMID 16869735 DOI: 10.1101/Sqb.2005.70.016 |
0.738 |
|
| 2005 |
Weir B, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee J, Janne P, Li C, Sellers W, Naoki K, Richards W, Sugarbaker D, Chen F, Rubin M, et al. High resolution SNP arrays identify amplified regions in lung cancer Cancer Biology and Therapy. 4. PMID 16710933 DOI: 10.4161/cbt.4.8.2003 |
0.616 |
|
| 2005 |
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436: 117-22. PMID 16001072 DOI: 10.1038/Nature03664 |
0.742 |
|
| 2005 |
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Research. 65: 5561-70. PMID 15994928 DOI: 10.1158/0008-5472.Can-04-4603 |
0.643 |
|
| 2005 |
Beroukhim R, Lin M, Park Y, Hao K, Zhao X, Garraway LA, Fox EA, Hochberg EP, Mellinghoff IK, Hofer MD, Descazeaud A, Rubin MA, Meyerson ML, Wong W, Sellers WR, et al. Inferring Loss-of-Heterozygosity from Tumors Without Paired Normals Using High-Density SNP Arrays Plos Computational Biology. DOI: 10.1371/Journal.Pcbi.0020041.Eor |
0.592 |
|
| 2005 |
Garraway LA, Sellers WR. Array-based approaches to cancer genome analysis Drug Discovery Today: Disease Mechanisms. 2: 171-177. DOI: 10.1016/J.Ddmec.2005.05.020 |
0.62 |
|
| 2003 |
Späth GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proceedings of the National Academy of Sciences of the United States of America. 100: 9536-41. PMID 12869694 DOI: 10.1073/Pnas.1530604100 |
0.511 |
|
| 2002 |
Garraway LA, Chabner B. MDR1 inhibition: less resistance or less relevance? European Journal of Cancer. 38: 2337-2340. PMID 12460776 DOI: 10.1016/S0959-8049(02)00490-2 |
0.351 |
|
| 1997 |
Garraway LA, Tosi LR, Wang Y, Moore JB, Dobson DE, Beverley SM. Insertional mutagenesis by a modified in vitro Ty1 transposition system. Gene. 198: 27-35. PMID 9370261 DOI: 10.1016/S0378-1119(97)00288-6 |
0.561 |
|
| 1994 |
Pimenta PF, Saraiva EM, Rowton E, Modi GB, Garraway LA, Beverley SM, Turco SJ, Sacks DL. Evidence that the vectorial competence of phlebotomine sand flies for different species of Leishmania is controlled by structural polymorphisms in the surface lipophosphoglycan. Proceedings of the National Academy of Sciences of the United States of America. 91: 9155-9. PMID 8090785 DOI: 10.1073/Pnas.91.19.9155 |
0.47 |
|
| 1993 |
Ryan KA, Garraway LA, Descoteaux A, Turco SJ, Beverley SM. Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of Leishmania Proceedings of the National Academy of Sciences of the United States of America. 90: 8609-8613. PMID 8378337 DOI: 10.1073/Pnas.90.18.8609 |
0.529 |
|
| Show low-probability matches. |